

Index

A

- ABCD-rings of bile acids, 882, 884, 886, 890–892, 895–901, 909
- ABC of EQA, 1172
- ABC-rings of bile acids, 883
- Abiraterone, 461
- AB-rings of bile acids, 840, 884, 887
- Accelerating voltage switching in MS of bile acids, 907
- Acetate derivatives of bile acids, 872, 873, 880, 882, 892
- Acetonide and alkylboronate derivatives of bile acids, 860, 877, 890
- 3 α -Acetoxy-7 α ,12 α -dihydroxy-5 β -cholan-24-oic acid, 17
- Addison's disease, 357
- Adducts in MS, 823, 827, 844, 879
- Adrenal cortex
 - biosynthesis of steroids in, 331, 334–336
 - in zona fasciculata, 331, 333
 - in zona glomerulosa, 331, 333
- Adrenocortical reserve
 - test for, 342
- Alclometasone dipropionate, 1101
- Aldehyde dehydrogenase in enzymatic assay of bile acids, 936
- Aldosterone, 11, 12, 185, 190, 206, 234
 - aldosterone:renin ratio, 385
 - analysis, 385–390
 - biosynthesis of, 237
 - concentration in human serum, 234
 - control of action, 385–386
 - effect of acid, 206
 - ester in cardiac tissue, 195
 - GC and LC-MS, 368–369
 - 18-glucuronide, 386, 389
 - γ -lactone, 387
 - LC-MS/MS, 234, 238
 - in saliva and faeces, 386
 - separation on Sephadex LH20, 190
 - serum assay by LC-MS/MS, 387–388
 - structure, 331
- Alkaline hydrolysis of conjugated bile acids, 859–860, 895, 897
- Alkaline phosphatase labeling in bile acid immunoassay, 939
- Alkyldimethylsilyl ethers of bile acids, 880
- Alkyl esters of bile acids, 910
- Alkylsilyl ethers of bile acids, 872–874, 882, 894
- All-Laboratory Trimmed Mean (ALTM), 703, 1172
- Allo-bile acids (5 α -isomers), 884, 893, 901
- Allocholane, 13
- Allocholic acid, 879
- Allonorcholic acid, 879
- Allopregnane, 13
- Allopregnanolone, 3, 563
- Allylic cleavage of bile acids, 892, 899
- Allylic structures of bile acids, 873, 890, 891
- Alphadolone acetate, 587
- Alphaxolone, 587, 590
- ALTM. *See* All-Laboratory Trimmed Mean
- Ambient analyte assay, 318
- Aminonide, 1101, 1109
- AME. *See* Apparent mineralocorticoid excess
- Ammonium chemical ionization (CI) in MS of bile acids, 910
- Amniotic fluid, bile acids in, 889
- Anabolic steroids
 - administration, 755–756
 - analysis of, 775–821
 - clinical use of, 743–745
 - confirmatory analysis, 795–801
 - diagnostic metabolites, 744–745
 - effects on health, 752–753
 - in food, 752

- Anabolic steroids (*cont.*)
- glucuronidation with recombinant UGTs, 773
 - LC-MS, 788–795, 797
 - legal control of, 745, 747–8
 - metabolism of, 757–775
 - misuse in sport and society, 748–749
 - positive results in sport (1994 and 2004), 750
 - screening by GC-MS, 785–788
 - structural modifications, 753–755
 - structures, 744–745
 - supplements and designer steroids, 749–752
 - trade names, 744–745
- Analogues of vitamin D, 1059–1061
- assays of, 1032
- Analysis of single estrogens or metabolites, 653–702
- Analyte heterogeneity, 1161
- Analytical goal, 1165
- Androgens, 1, 457–538
- abbreviations, 457
 - activation and inactivation pathways, 460, 462
 - adrenal, 535–537
 - 21-hydroxylase deficiency, 535
 - steroid glucuronides in adrenal hyperplasia, 537
 - T levels in congenital adrenal hyperplasia, 536
 - 7 α - and 7 β -dehydroepiandrosterone (DHEA), 458, 460, 492–493, 501, 509
 - in the brain, 493
 - 5 α -androstane-3 α ,17 β -diol, 468, 505
 - androstenedione, 458, 459, 462, 516–521, 529
 - androgenic activity, 458
 - catabolism, 462
 - conversion to testosterone, 459
 - estimation, 516–521
 - in horse testis, 529
 - aromatization, 608, 609, 616
 - biosynthesis, 458–460
 - brain, 486–491, 493
 - C₁₉ steroid biosynthesis in, 493
 - importance of CYPs 7 α and 7 β , 493
 - capillary electrophoresis, 479–480
 - catabolic reactions of C₁₉ steroids, 460–462, 466–468
 - uridine phosphoGTs (UGTs), 466–467
 - chemiluminescent immunoassays (CIAs), 516–521, 529–533
 - aminophthalhydrazides, 529
 - 7 α -bio-T immuno-chemical tracers, structure, 532
 - horseradish peroxidase (HRP), 532
 - luminogenic properties, isoluminol, 530
 - testosterone glucuronide aminobutyl-ethyl-isoluminol conjugate structure, 531
- combined GC-MS-selected ion monitoring, 485–500
- chemical ionization-negative ion (CI-NI), 498–500
 - and CYP 3A4 and CYP 3A5 proximal promoter, 494
 - and cytochrome P-450, 493
 - and DHEA, 492
 - and 5 α -DHT, 492
 - HPLC/RIA, 497
 - and human hair, 497–498
 - and 7 α -hydroxylase, 493
 - and 15 α -hydroxytestosterone, trimethylsilyl (TMS) derivatives, 494–495
 - and recombinant human CYP1B1, 494
 - retention times and mass fragments, TMS derivatives, 496
 - TLC/GC-MS, 493
- conjugates of C₁₉ steroids, 460, 466–471, 504–509
- conjugation, 460, 466–469
 - extraction of, 470–471
 - measurement of androsterone-and 5 α -androstane-3 α ,17 β -diol-glucuronides, 505
 - measurement of DHEA and intact DHEAS in human serum by capillary GC-MS, 506
 - measurement of glucuronides in urine of male subjects, 505
 - quantification by GC-MS methods, 504–509
 - rapid indication of women with androgen deficiency, 505–506
- cytochromes P450, 459–461, 493–496
- in biosynthesis of androgens, 459, 461
 - changes of spin state with binding of T, 494
 - characteristics of the genes, 461
 - CYP3A4 catalysis of 6 β -hydroxylation, 494
 - effects of 6-hydroxylation on 3-oxo-4-ene steroid, 494–496

- mass fragmentation of hydroxylated steroids in GC-MS-SIM, 496
- presence of CYP 7 α and 7 β in brain, 493
- derivatisation of C₁₉ steroids, 481–482, 500
 - for capillary GC, 481
 - pentafluorobenzyl oximes (PFBO), 500
 - useful derivatives, 482
 - useful ions for monitoring, 482
- 3 α ,17 α -dihydroxy-5 α -pregnan-20-one, 460
- 4-Ene-5 α -reductase (5 α -R), 458
 - activities of forms 1 and 2, 458
 - in prostate, 458
 - in testosterone reduction, 458
- enzyme molecular biology, 461
- GC-MS, 480–511
 - chemical ionization-negative ion (GC-MS-CI-NI), 498–499
 - combined GC-MS and selected ion monitoring, 485
 - combined with liquid chromatography LC-MS-MS, 501–502
 - derivatisation of C₁₉ steroids, 481–483
 - LC-Electrospray ionization-MS-MS, 502–504
 - on-line methodology, 509–511
 - quantification of C₁₉ steroid conjugates, 504–509
 - glucuronides, 504–506
 - sulphates, 506–509
 - quantification of C₁₉ steroids, 486–491
 - stable isotope MS, 484
 - tandem MS or MS-MS, 500–501
 - use of internal standards, 483–485
 - use of specific ion monitoring (SIM), 485, 492–500
- glucuronides, 468
 - direct quantification of intact glucuronides, 476, 504–506
 - formation, 466
 - UGT involvement, 467–468
- high-energy collision-induced dissociation (CID), 503–504
 - of Girard T and P derivatives, 503–504
- high performance liquid chromatography, 473–478, 486–491, 502, 510
 - use in analytical studies, 475–476
 - use in metabolic studies, 473–476
 - use in on-line GC-MS measurements of T hydroxyl components, 510
 - use prior to LC-electrospray ionization MS-MS, 502
 - use in purification of 7 α / β -hydroxy DHA in brain, 502
 - use in quantification of steroid conjugates, 476–478
- high temperature liquid chromatography, 478
- human hair, C19 steroids in, 497–499
- 6 β -hydroxylase and 7 α -hydroxylase, 468
- hydroxylation, 468, 494–495
 - 15 α -hydroxytestosterone, 494–495
- immunoassays, 511–538
 - chemiluminescent immunoassays (CIAs), 516–521, 528–533
 - direct (non-extraction) assays, commercial kits, 513–521, 524
 - enzyme immunoassay (EIA), 516–521, 528–529
 - enzyme-linked immunosorbent assays, 516–521, 526–528
 - extraction and purification, 469–470, 506, 509, 513
 - potential bridging molecule synthesis, 512–513
 - radioimmunoassay (RIA), 502, 516–521, 535–537
 - testosterone in plasma, 516–526
 - time-resolved fluorimetric immunoassays, 516–521, 533–535
- internal standards for quantification, 483–484, 497–498
 - quantification, 483–484
 - use of in GC-MS-SIM, 497, 498
- LC-electrospray ionization-MS-MS, 468, 502–506
 - by rapid filtration transport assays, 468
- LC-MS-MS, 501–509
 - of DHEA, 502
 - 7-hydroxylation of DHEA, 502
 - in quantification of C₁₉ steroids, 502
- liquid-liquid extraction, 469–470, 486–491
- mass spectrometry, 480–511 (*see also* GC-MS)
- metabolic studies, 473–475
- MS-MS, 486–491, 500–501 (*see also* Tandem MS)
- multi-enzyme cytochrome complex CYP19, 608
- neuroactive C₁₉ steroids (NAS), 492–493
 - actions in brain, 492–493
 - DHEA(s) and pregnenolone(s), 492–493
 - DHEA as potential anti-depressant, 492
 - measurement by GC-MS-SIM, 492–493

Androgens (*cont.*)

- prostate, 458, 467, 491, 521, 537
 - androgens measured by RIA, 537
 - modulation of 5 α -reductase, 458
 - in prostate cancer, 521
 - 5 α -steroid reductase, 491
 - UTPs and prostate tumour cells, LNCaP, 467
- purification of C₁₉ steroids, 463–465, 472–478
 - HPLC, 473–478
 - HTLC, 478
 - procedures, 472–473
- quantification, internal standards, 483–484
- radioimmunoassay (RIA), 502, 516–521, 535–537
 - use as compared with LC-MS-MS, 502
 - use in prostate, 537
- rapid filtration transport assays, 468
- sample preparation, 513
 - conjugated steroids, 513
 - unconjugated steroids, 513
- separation and quantification, 473–480
 - analytical studies, 475–476
 - capillary electrophoresis, 479–480
 - glucuronides, 476
 - high performance liquid chromatography, 473–478
 - high temperature liquid chromatography, 478–479
 - metabolic studies, 473–475
 - sulphates, 476–477
- solid-phase extraction (SPE), 470–471, 486–491, 506, 509
 - extraction of urine for estimation of intact DHAS, 506
 - pre-extraction for GC-MS on line, 509
- specific ion monitoring (SIM), 483, 485, 492–500
 - use in estimation of T in humans, 496, 497, 499
 - use in neuroactive C₁₉ steroids in brain, 493
 - use of internal standards, 483
- stable-isotope MS, 484–491
- structures and names, 459, 462
- sulphates, 476–477, 506–509
 - direct quantification of intact sulphates, 476–477
 - measurement of DHEA and intact DHEAS in human serum by capillary GC-MS, 506–509
 - quantification by GC-MS methods, 506–509
- supercritical fluid extraction (SFE), 472
- tandem MS or MS-MS, 486–491, 500–501
 - description, 500
 - measurement of C₁₉ steroids, 486–491
 - measurement of DHEA and pregnenolone in rat olfactory bulbs, 501
- testes, 463, 528, 529
 - 4-Androstenedione in horse, 529
 - measurement of T in horse cryptorchidism, 528
 - measurement of T metabolites in rat liver, 463
- testosterone, 459–460, 462, 479–480, 498, 505, 516–526, 531, 534
 - biosynthesis, 459
 - catabolism, 460, 462
 - measurement of different forms in plasma, 516–526
 - measurement of T and TG in male urine, 505
 - measurement of T in human hair, 498
 - proposed structure for europium labelled T alkyl oxime derivatives, 534
 - proposed structure for T glucuronide, 531
 - separation of T and its hydroxy derivatives by capillary electrophoresis, 480
 - structures of T and its hydroxy derivatives, 479
 - uridine phosphoGTs (UGTs), 466, 467
- Androsta-1,4-diene-3,17-dione, 11, 12
- 5 α -Androstan-3 α -ol, 9
 - Carbon-13 shifts in NMR, 98
 - proton chemical shifts of steroids, 96–97
- 5 α -Androstan-3 β -ol, 9
 - Carbon-13 shifts in NMR, 98
 - proton chemical shifts of steroids, 96–97
- Androstane, 1
- 5 α -Androstane
 - Carbon-13 shifts in NMR, 98
 - proton chemical shifts of steroids, 96–97
- 5 β -androstane (testane), 98
 - Carbon-13 shifts in NMR, 98
 - proton chemical shifts of steroids, 96–97
- 5 α -Androstan-16-one, 43
- Androst-4-en-3,17-dione (4-A), 10
- Androst-5-ene-3 α ,17 β -diol 17-acetate, 17
- Androstenedione, 10, 230, 233, 239, 241, 459, 462, 485, 516–521, 607, 608, 611
 - in alligator egg yolk, 186
 - aromatisation of A ring, 608
 - in blood spots, 232

- in CAH, 232
 - concentration in serum, 229, 236
 - as estrogen precursor, 607, 611, 614
 - LC-MS/MS, 236
 - in neonatal saliva, 226
 - structure, 331, 608
 - use of celite for separation from androstenedione, 186
- Androsterone, 1, 13
- Angular methyl group in bile acids, 880, 887
- A-nor-5 α -androstane, 19
- A-nor-5 α -androstane-2-one, 43
- 3-(1-Anthroyl) derivative of bile acids, 870, 871
- Antibody
- antibody occupancy, 316–317
 - anti-idiotypic, 315, 317–318
 - characterization
 - affinity and avidity, 290
 - antibody titer, 289–290
 - bridge recognition problems, 291–292
 - cross-reaction, 292–293
 - screening assay, 289
 - specificity, 291, 301, 302, 1161
 - coated solid phase, 289, 307, 317
 - equilibrium constant, 284
 - haptens, 285
 - heterophilic, 311, 313, 314
 - IgG, 284–285
 - immunogen production, 286
 - monoclonal antibody production, 287–288
 - polyclonal antibody production, 286–287
 - saturation analysis, methods, 288
 - second antibody techniques, 307–308
- Antigen-antibody reactions in IAs for bile acids, 938, 939
- Anti-idiotypic antibodies, 1162
- Antisera for bile acid IA, 938, 939
- Apparent mineralocorticoid excess (AME), 233, 334, 377, 396, 403
- A-ring of bile acids, 883, 887, 890
- Artifacts (artefacts) formed during bile acid assay, 848, 854, 858, 860, 873, 874, 878, 888, 891, 898
- A score, 1172
- Atmospheric pressure chemical ionisation (APCI), 123–125
- Atmospheric pressure ionization (API) in MS of bile acids, 913, 921
- Atmospheric pressure photo-ionisation (APPI), 125–126
- Atom % excess in determination of pool size for bile acids, 910
- Automated immunoassays for progesterone, 573
- Axial bond, 8
- Axial-equatorial *cis*-glycol in bile acids, 876
- Axial hydroxyl groups in bile acids, 863, 870, 876, 877
- B**
- Bacterial luciferase in sensitive enzyme assay for 7-hydroxy bile acids, 937
- BALCO affair, 751–752, 754–755
- Base peak in MS of bile acids, 884, 886, 887, 889, 890
- Batch rejection rules, 1166
- Bathochromic effect, 32
- BCD-rings in bile acids, 884
- Beclomethasone
- LC-or GC-MS, 414–423
 - structure, 406
- Beclomethasone dipropionate, 1101, 1122, 1123, 1131, 1142
- Benzyl esters of bile acids, 910
- Bergmeyer Conferences, 1159
- Betamethasone
- acetate, 1101, 1123
 - benzoate, 1101, 1109
 - compendial analysis of, 1101, 1109, 1110, 1117, 1118, 1124, 1130, 1131, 1140, 1148, 1153
 - dipropionate, 1101, 1109, 1129, 1130, 1147, 1153
 - sodium phosphate, 1101, 1109
 - valerate, 1101, 1109, 1118, 1145
- (16 β)-Betamethasone
- LC-or GC-MS, 414–423
 - structure, 406
- Bias, 1159, 1161, 1167
- graphical representation of, 1172–1177
- Biased analysis for bile acids, 841, 879, 907, 941
- Bile, 845–847, 889, 893, 895, 911, 937
- Bile acid/bile alcohol nomenclature, 840
- Bile acid-protein conjugates, 843, 844, 923, 939
- Bile acids, 11, 837–966
- adenylates, 843, 931
 - age dependent differences, 847
 - in bile, 846, 889, 893, 895, 896, 898, 899, 913, 930, 937
 - biosynthesis, 840, 882, 892, 895, 898, 899, 931
 - in birds, 894
 - in brain, 848, 851, 922

- Bile acids (*cont.*)
- CoA thioesters, 843, 931
 - conjugates, 842–845, 879, 913, 914, 921–923, 928, 930, 938, 939
 - in early life (gestation), 847, 883, 884, 886, 889
 - enzymatic assays, 935–938
 - in faeces, 842, 848, 851, 855, 858, 869, 870, 873, 884, 889, 893, 909, 937
 - fatty acyl esters, 842, 845
 - in frogs (*Rana plancyi* and *Rana catesbi-ana*), 901
 - galactosides (Gal), 845, 861, 923, 926, 927
 - GC, 872–878
 - GC-MS, 878–913
 - in geese, 866, 893
 - glucosides (Glc), 844, 857, 861, 902, 918, 923, 926, 929
 - glucuronides, 844, 854–855, 861, 866, 867, 869, 870, 884, 896, 901, 902, 909, 918, 921, 923–925, 929, 936
 - glycine-conjugated, 842–845, 854–855, 859, 862, 863, 865, 866, 868–870, 872, 878, 901, 902, 918, 919, 928, 930, 938
 - immunoassay, 938–940
 - kinetics, 909, 912
 - LC, 861–872
 - LC-MS &-MS/MS, 913–935
 - N*-acetylglucosaminides, 844–845, 857, 861, 902, 909, 918, 929, 932, 933, 939
 - in pigs, 846, 847, 868, 889, 891
 - in plasma (serum), 849–853, 857, 858, 866, 869–873, 886–888, 892, 895, 896, 898, 909–911, 913, 914, 923, 930, 931, 935–939
 - pool size, 910
 - in reptiles, 893, 897, 898
 - in rodents (rats and mice), 841, 843–846, 848, 849, 851, 860, 866, 870, 889, 892, 893, 898, 923, 930, 931, 938, 944
 - in seals, 898
 - separation of free and conjugates, 220
 - sex differences, 846
 - side-chain, 840, 841, 844, 866, 869, 870, 880–882, 888, 894, 896–901, 918, 932
 - in small intestinal fluid, 851, 898, 937
 - species differences, 846
 - sulphates, 843, 844, 854–855, 857, 859, 860, 866, 870, 891, 896, 902, 909, 919, 923, 930, 932, 937–939
 - in swans, 866, 893
 - taurine conjugated, 843, 844, 854–855, 857, 859, 862, 863, 865–872, 893, 898, 899, 901, 902, 917, 921, 928, 930, 938
 - in tree ducks, 866, 893
 - unconjugated (free), 854, 855, 862, 863, 869, 870, 886, 922, 930, 938
 - in urine, 850, 857, 870, 877, 884, 887, 889, 892, 895–897, 902, 911, 913–915, 918, 921, 923, 926, 930, 933, 934, 937, 938
- Bile alcohol glucuronides, 854, 855, 896, 919, 921
- Bile alcohols, 841, 854, 880–883, 890, 891, 896, 897, 899, 919, 921
- Bile alcohol sulphates, 842, 854
- Biliary atresia, 911
- Bilirubin–interference in enzymatic assay for bile acids, 936
- Binding proteins, 164, 1161
- Biological matrix–during GC-MS of bile acids, 907
- Biological samples used in doping control, 775–781
- blood, 778
 - hair, 778–781
 - other matrices, 778
 - urine, 775–778
- Biological variation, 1165
- Bioluminescence detection (assay) for bile acids, 937
- Bioluminescence in immunoassay, 296
- Biosensors–use of in immunoassay, 320–321
- Biosynthesis of steroids, 238
- Biotin-steroid conjugates, 570
- Bolasterone, 744
- detection by SIM in urine, 786
 - metabolite in urine, 786
- Boldenone, 744, 757
- metabolism, 760–761
 - as ‘natural’ steroid in the horse, 814
- Boldione, 746
- Bond-Elut SAX for separation of bile acid conjugates, 855
- Box and Whisker plots, 1173
- Brain and estrogens, 609, 616, 671, 678
- Branched chain acyl-CoA oxidase–in formation of primary bile acids, 895
- Brassinolide, 5
- Carbon-13 shifts in NMR, 98

- proton chemical shifts of steroids, 96–97
- Bridge effect in steroid radioimmunoassay, 568
- B-ring fragmentation/fission in MS of bile acids, 890–892
- Brominated derivatization reagents for LC of bile acids
 - α -Bromoacetophenone 869
 - 2-Bromoacetyl-6-methoxynaphthalene, 870
 - 1-Bromoacetylpyrene, 870
 - 4-Bromomethyl-6,7-dimethoxycoumarin, 870
 - 4-Bromomethyl-7-methoxycoumarin, 870
 - 3-(4-Bromomethylphenyl)-7-diethylaminocoumarin, 870
 - p*-Bromophenacyl bromide, 869
- B score, 1172
- Budesonide, 1101, 1122, 1124, 1140, 1145, 1146
 - compendial analysis, 1101, 1122, 1124, 1140, 1145, 1146
 - LC-or GC-MS, 384, 410, 414–423
 - metabolism, 407
 - MS/MS transitions, 412
 - silylation, 412
 - structure, 406
- Bufanolide, 22
- t*-Butyldimethylsilyl (TBDMS) ether of bile acids, 874
- Butyl esters of bile acids, 873
- BXL-628. *See* Elocalcitol

- C**
- Calbindin, 978, 980
- Calcidiol, 21. *See also* 25-Hydroxyvitamin D₃
- Calciol, 21
- Calcipotriol (MC903), 985, 986
 - assay in plasma, 1060
 - characterization of metabolites, 1052
 - ¹³C-NMR data, 1042
- Calcitriol, 21
- Calcitriol, 21. *See also* 1 α ,25-Dihydroxyvitamin D₃
- Calcitroic acid
 - formula and origin, 973, 979, 980
- Calibration of quadrupole mass filters, 883
- Calusterone, 744
- Campesterol, 7
- Cancer and estrogens
 - anti-cancer agents, 611, 617
 - breast, 609, 611, 616–619, 621, 628–630, 639, 653, 669, 673, 676, 677, 681, 688, 705
 - cervical (HPV-induced), 617–619
 - effect of diet & exercise, 618
 - prostate cancer, 617–619, 674, 678
 - risk assessment, 618, 677, 678, 705
 - treatment, 614, 617, 621, 647, 653, 655, 673
- CAP. *See* College of American Pathologists
- Capillary electrochromatography (CEC) of bile acids, 868
 - in compendial analysis, 1099, 1132, 1136, 1139, 1141–1143, 1147, 1148, 1150, 1152
 - CEC-MS, 1132, 1133, 1139, 1146
- Capillary electrophoresis (CE) in compendial analysis, 1099, 1127–1129, 1131, 1132, 1139, 1141, 1142, 1144, 1147, 1148, 1150, 1151
- Capillary GC-columns for bile acids, 874, 875
- Capillary LC-columns for LC-MS of bile acids, 933–935
- Carbon isotope ratio. *See* ¹³C:¹²C ratios
- Carbon-13 chemical shifts of steroids, 98
- Carbon-13 NMR spectra
 - broadband decoupling, 80
 - chemical shifts, 81
- Carbonyl group. *See* Oxo group
- Carboxyl group of bile acids, 865, 867, 869, 870, 872, 918, 923, 930
- Carboxymethyl group-loss identifies 25-hydroxy-bile acids, 900
- Cardanolide, 22
- Catabolism of steroids, 246
- Catechol estrogens, 611, 646, 670, 676–678, 681, 687, 690
 - assay methods, 676
 - assays for 2-hydroxyestrone & 16 α -hydroxyestrone, 677
 - assays for 2-hydroxy & 4-hydroxyestrone/estradiol, 377
 - cancer prevention, 676
 - carcinogenesis, 688
 - catechol-O-methyl transferase COMT, 676, 678
 - conjugates, 611
 - depurinating adducts of catechol estrogens & glutathione conjugates, 611, 687
 - DNA damage, 611, 681, 688
 - 17 α -estradiol adducts, 690
 - exercise & 2-hydroxyestrone levels, 618
 - GC-electron capture, 646

- Catechol estrogens (*cont.*)
 GC-MS assay, 634–635, 656, 678
 glutathione conjugates, 687
 4-hydroxy-estradiol-N3-adenine, 688
 4-hydroxy-estradiol-N7-guanine, 688
 immunoassay, 676
 LC-MS & MS/MS, 670, 678, 690
 P450 cytochrome enzymes, 610
 quinones, 611
 reaction with thiols, 687
 semiquinones, 611
 Sephadex LH-20 separation, 676–677
 stability, 676
 urine, 617, 640, 659
- CBG. *See* Cortisol binding globulin
- C₂₀ bile acids, 841, 881
 C₂₁ bile acids, 841, 881
 C₂₂ bile acids, 841, 881
 C₂₃ bile acids, 841, 879, 881
 C₂₄ bile acids, 841, 881, 886, 887, 895, 900
 C₂₅ bile acids, 841, 859, 881. *See also*
 Homo-bile acids
- C₂₇ bile acids, 881, 886–888, 895, 897, 899,
 900, 911. *See also* Long-chain
 bile acids
- ¹³C:¹²C ratios
 ‘delta per mil’ notation, 817
 in detection of steroid doping in sport,
 816–821
 origin of different ratios in steroids, 817
 use of GC/C/IRMS, 816, 817, 821
- C₂₀ dicarboxylic bile acid, 896, 911
- C₂₀,7,8 double bond in bile acids, 892
- Cerebrotendinous xanthomatosis (CTX),
 882, 896, 898, 921
 and *CYP27A1* mutation, 974
- Chair conformation, 8
- Charged aerosol detector-during LC of bile
 acids, 869
- Charge-remote fragmentation (CRF) during
 MS of bile acids, 914, 915, 921
- Chemical ionization (CI)—use in MS of bile
 acids, 879, 901, 910
- Chemical shift, 67–68
- Chemiluminescence, in compendial analysis,
 1117, 1138, 1142, 1145, 1146
- Chemiluminescence in immunoassay
 acridinium derivatives, 297–298
 bioluminescence, 296
 chemiluminescence enzyme
 immunoassay, 298
 electrochemiluminescence, 296
 isoluminol and derivatives, 296–297
 thermochemiluminescence, 296
 types, 295–296
- Chemiluminescent immunoassays (CIAs)
 of androgens, 516–521, 529–533
- Chenodeoxycholic acid (CDCA), 11, 13,
 837–966
- Chiroptical properties
 circular dichroism (CD), 43–47
 Cotton effect, 42–46
 octant rule, 44, 46
 optical rotatory dispersion, 42–45
 specific optical rotation, 42
- Chlormadinone acetate, 1101
- Chlorodehydromethyltestosterone, 744
- 9-Chloromethylantracene—use for LC of bile
 acids, 869
- N*-Chloromethyl-4-nitrophthalimide—use for
 LC of bile acids, 869
- Cholane, 1, 13
 5 α -Cholane, 13
 5 β -Cholane, 13
- Cholecalciferol, 21, 969, 1101, 1110. *See also*
 Vitamin D₃
- Cholesta-4,6-dien-3 β -ol, 30
 Cholesta-5,7-dien-3 β -ol, 29
- Cholestane, 1, 13
 5 α -Cholestane, 13
 5 α -Cholestane (as internal standard), 912
- Cholestane-3,5-diol isomers, 889
 (23*S*)-5 β -Cholestane-3 α ,7 α ,12 α ,23,25-pentol,
 899
- 5 β -Cholestane-3 α ,7 α ,12 α ,23,26-pentol, 897
- Cholestanic acids, 859, 881, 895–897,
 899–901, 931
- Cholestatic disease, 843, 855, 866, 869,
 883, 889, 891, 911, 914, 918,
 921, 934, 938
- (24*R*)-Cholest-5-en-3 β -ol, 12
 5 β -Cholest-24-en-3 α ,7 α ,12 α -triol, 900
 5 β -Cholest-25-en-3 α ,7 α ,12 α -triol, 900
- Cholesterol, 851, 886, 894, 908
 Carbon-13 shifts in NMR, 98
 proton chemical shifts of steroids, 96–97
 structure, 331
- Cholic acid, 1, 11, 13, 844, 851, 863, 867,
 875, 879, 893, 902, 909, 910, 912,
 928, 937, 938, 1122
- Cholic acid 7-sulphate, 844, 870, 936
- Cholyglycine hydrolase, 859
- N*-Cholytaurine, 18
- Chromate oxidation of bile acids, 902
- Chromatographic (LC) behaviour of bile acids,
 862–872
- Chromophores, 29
 aromatic chromophores, 40
 conjugated dienes and trienes
 buta-1,3-diene, 34

- cross-conjugated diene, 38
 - 5,7-diene, steroidal, 35
 - steroidal 5,7,10(19)-triene (vitamin D series), 36
 - 3,5,7-triene, steroidal, 35
 - conjugated unsaturated ketones
 - digitoxigenin, 39
 - enones, calculations, 38
 - Woodward-Fieser-Scott rules, 36–37
 - Circadian rhythms, 342
 - Circular dichroism (CD), 43–47
 - in compendial analysis, 1117, 1138, 1144, 1151
 - [¹³C] labeled analogs of bile acids
 - 908–910, 913
 - [¹⁴C] labeled analogs of bile acids 896
 - Clinical analysis of bile acids, 871, 933, 937
 - Clinical governance, 1156
 - Clinical Pathology Accreditation (CPA) UK Ltd., 1168
 - Clobetasol propionate, 1101, 1109, 1123
 - in skin whitening, 409
 - Clobetasone butyrate, 1101
 - Clocortolone pivalate, 1101, 1111
 - Clostebol, 744
 - metabolism of acetate ester
 - in the horse, 762
 - College of American Pathologists (CAP), 1184
 - Collision-induced dissociation (CID), 129, 130
 - during MS/MS of bile acids, 913–932
 - Colorimetric method for detection of bile acids, 936, 937
 - Column chromatography
 - aluminium oxide, 187
 - celite, 186
 - florisil, 186
 - lipidex, 188
 - modified Sephadex, 191–192
 - Sephadex LH-20, 188–190
 - SPE sorbents 188–189, 192
 - Column-immobilized 3 α -HSD for LC of bile acids, 871, 937
 - Competitive immunoassay, 1162
 - 5 α -Conane, 23
 - Concentration of steroids
 - in serum, 234–236
 - in urine, 250–251
 - Conessine, 23
 - (E) Configuration, 18
 - (Z) Configuration, 18
 - α -Configuration, 3
 - Confirmatory analysis of steroids
 - WADA Guidelines, 795–801
 - Conformational analysis of vitamins D compounds
 - A-ring, 1044–1048
 - side chain, 1049–1052
 - structure-function correlation, 1040
 - Congenital adrenal hyperplasia (CAH), 233, 238
 - corticosteroid secretion in, 340, 378–382, 401
 - Conjugates, 9
 - hydrolysis, 180–182
 - separation by modified Sephadex, 191
 - separation by SPE sorbents, 178
 - Conjugation of anabolic steroids, 771–775
 - Contaminants in bile acid analysis, 907, 936.
 - See also* Artifacts (artefacts) formed during bile acid assay
 - Continuous-flow determination during LC of bile acids, 937
 - Continuous flow FAB-MS linked to LC for bile acid analysis, 867, 921
 - Contraception and estrogens, 619
 - Conversion rule, 5, 6
 - Coprostanone, 13
 - Coprostanic acids, 895–896. *See also* THCA
 - Corticosteroids, 11, 329–455
 - analysis of, 340–357
 - extraction, 342–345
 - purification, 343
 - quantitation, 346–357
 - analytical methods
 - chemical, 346
 - DELFLIA, 346
 - fluorescence, 346–347
 - polarisation IA (Abbott TDx), 360
 - quality assurance, 359
 - automated immunoassays for, 346–355
 - biological activity, 332–334
 - biosynthesis, 331, 334–336
 - immunoassays, 346–355
 - in body fluids, 362–373
 - catabolism
 - carboxylic acids, 338
 - GC
 - electron capture, 387
 - LC-MS & GC-MS, 349, 356–357, 362–373
 - matrix effects and adducts in, 388–399
 - metabolism, 336–339
 - inborn errors of, 396, 399, 402
 - 11 β -OHDs
- Corticosteroids (*cont.*)
 - 20-OHDs
 - 5-reductases
 - structures, 330–331
 - urinary excretion of catabolites, 341

- Corticosterone, 12, 13
 analysis, 390
 GC and LC-MS, 369–371
 structure, 331
- Cortisol, 11, 12, 175, 180, 194, 233, 235, 249
 biosynthesis, 237, 378–383
 Carbon-13 shifts in NMR, 98
 compendial analysis, 1103, 1107, 1108,
 1110–1113, 1119, 1122–1125, 1127,
 1129, 1131, 1141, 1147, 1149, 1151
 acetate, 1103, 1110, 1111, 1114, 1119,
 1122, 1125, 1128, 1141, 1145, 1151
 butyrate, 1103, 1110
 hydrogen (hemi)succinate, 1103, 1128
 sodium phosphate, 1103, 1111,
 1122, 1143
 sodium succinate, 1103, 1114, 1147
 valerate, 1103, 1110
- GC-and LC-MS, 362–368
 immunoassay of, 291, 303, 306, 313, 319
 cross reactions, 313
 free cortisol, 319
 interference, 349, 357
 saliva, 303
 specificity, 291
 urine, 306
- LC assay, 207, 209–211, 217–219
 LC-MS/MS, 229, 232–233, 235–237
 in other body fluids/tissues, 378
 part of comprehensive urinary profile, 251
 proton chemical shifts of steroids, 96–97
 in saliva, 208, 212, 374–375
 separation from 11-deoxycortisol, 188–189
 in serum, 235
 structure, 331
 TLC assay method, 193, 361
 in urine, 375–378
 urine free cortisol, 173, 213, 216, 219, 226
 use of column switching, 226
 use of micellar chromatography, 221
- Cortisol binding globulin, 342
- Cortisone, 12, 13, 1131
- Cortisone acetate, 1101, 1109, 1110, 1116
- Cotton effect, 42–46
- Coupling constants
 allylic couplings, 80
 geminal coupling 2J (H,H), 79
 homoallylic couplings, 80
 J(C,C), 104
 J(C,H), 102–104
 J(H,H) values, 99, 102
 vicinal coupling 3J (H,H), 79
 W coupling, 80
- CPA (UK) Ltd., 1168
- Crassinolide, 5
- Creams
 compendial analysis, 1109–1112, 1118,
 1119, 1122, 1124, 1125, 1127,
 1145, 1148, 1151
- Cross-reactivity in IA of bile acids, 939
- C score, 1172
- CSCQ, 1184
- C₁₉ steroids. *See* Androgens
- Cubulin, 975, 977, 980
- Cushing's disease/syndrome, 233, 357–358,
 374–377, 396, 401, 403, 409
- Cyclic boronate esters of bile acids, 877, 890
- Cyclic diethylsilylene derivatives of bile acids,
 876–877, 911
- β-Cyclodextrin in LC of bile acids, 868–869
- Cyclodextrins, 178, 180, 182, 183, 206, 207,
 209–211, 218, 221, 223
- Cyclopentenoperhydrophenanthrene, 1
- CYP27A1* in biosynthesis of bile acids, 882,
 896, 921
- CYP7B1* in biosynthesis of bile acids, 882
- Cyproterone acetate, 590, 1101, 1112, 1116,
 1118, 1119, 1121, 1122, 1142,
 1146, 1149–1151
- Cytochromes P450 (CYP)
 in androgen metabolism, 459, 461
 in bile acid metabolism, 841
 CYP3A4, 974, 1064
 CYP24A1, 973
 CYP27B1, 973
CYP27B1 knock-out mouse model, 975
 CYP2J3, 974
 CYP2R1, 974, 980–981, 1064
 in estrogen metabolism, 610
 inborn errors in 396, 400, 921
 oxido-reductase defect, 398–399
 properties in brain, 584
 in steroid synthesis, 331–336
 terminology, 334
 in vitamin D₃ metabolism, 973–975
- D**
- Danazol, 1101, 1109, 1118, 1123, 1127, 1134,
 1140, 1143
 metabolism in the horse, 761
- Dansylhydrazones of bile acids, 872, 938
- DBP. *See* vitamin D binding protein
- DBP-binding affinities
 of vitamin D₃ metabolites, 972
- DEAE-Sephadex for separation of bile acid
 conjugates, 855
- DEAP-LH-20 for separation of bile acid
 conjugates, 853
- Defocusing during GC-MS of bile acids, 907

- Degradation, degradant (in compendial analysis), 1099, 1111, 1114, 1119, 1122–1125, 1132, 1134, 1135, 1137–1139, 1142–1149, 1151–1153
- Dehydrocholesterol, 852, 892
- 7-Dehydrocholesterol, 11
formula, 968
in skin, 968–970
 effect of UV light, 969
 reduced amount in skin in elderly, 969
UV spectrum, 971
- Dehydrocholic acid, 1101, 1111
- Dehydroepiandrosterone (DHEA), 3, 10, 239, 674
anabolism/catabolism, 467
aromatization of, 475
binding to androgen receptor, 458
in brain, 474, 493
Carbon-13 shifts in NMR, 98
chemical structure, 331, 459,
chemiluminescence immunoassay, 530
enzyme-linked immunoassay of, 527
equine metabolism of, 484–485
and GABA receptor
GC-MS of, 486–494
in hair by GC-MS, 497–498
in human hair, 470, 499, 501
7 α -hydroxylation of, 468, 475, 502
immunoassay of, 516–521
induction of 7 α -hydroxylase, 468
IUPAC systematic name, 457
metabolism to active androgens, 458
metabolite identification by LC-MS, 502
neuroactive steroid, 468, 492–493
7-oxo-DHEA, 476–477
as potential anti-depressant, 492
proton chemical shifts of steroids, 96–97
urinary excretion as sulfate, 460
weak androgen, 458
- Dehydroepiandrosterone sulfate (DHEAS),
17, 674
anabolism/catabolism, 467
in brain, 474
commercial immunoassays for, 536
enzyme-linked immunoassay of, 527
excretion in urine, 460
GC-MS of, 486–494
hydrolysis of, 471
immunoassay, 313, 516–521
LC of, 477–478
LC-MS/MS in serum, 473, 506–509
neuroactivity, 492
- Dehydrogenase reactions during enzymatic
assay of bile acids, 936–937
- Dehydroisoandrosterone [dehydroepiandrosterone (DHEA)], 607
- Dehydropregnenolone, 11, 12
- Dehydroxylation of bile acids, 841, 842, 891
- Densitometry. *See* Thin-layer chromatography (TLC)
- Deoxycholic acid (DCA), 11–13, 845,
846, 862–865, 867, 870, 871, 875,
893, 902, 909, 911, 912, 923, 925,
937, 939
- Deoxycorticosterone, 12, 13
- 11-Deoxycorticosterone (DOC), 13
analysis, 390
excess in CAH, 385
structure, 331
- 11-Deoxycortisol, 238
analysis of, 381–382
structure, 331
- 21-Deoxycortisol, 233
analysis, 380–381
- DEQAS (QA for 25-OHD), 1056, 1059, 1183
- Derivatization, 28, 107, 131–135
dansyl chloride, 230
girard hydrazone, 229
2-hydrazino-1-methylpyridine, 230
oxime, 230, 247
- Derivatization for FAB-and ESI-MS of bile
acids, 918, 930, 932
- Derivatization for GC of bile acids, 872–881,
886, 890, 901, 910, 911
- Derivatization for LC of bile acids, 869–872,
918, 930, 931
- Detection limits for bile acids, 868–870, 872,
913, 922, 935, 937–939
- DES (diethylstilboestrol), 10
- Designer drugs, 751, 791
- Desogestrel, 1101
- Desoximetasone, 1101
- Desoxycort(ico)sterone acetate, 1101, 1111
pivalate, 1101
- Deuterium (^2H) NMR, 82
- Dexamethasone
compendial analysis of, 1102, 1110–1113,
1119, 1121, 1123–1125, 1131,
1134, 1139, 1140, 1145, 1147,
1149, 1151
acetate, 1102, 1110, 1122, 1123, 1153
- Dexamethasone (*cont.*)
sodium phosphate, 1102, 1110, 1119
isonicotinate, 1100, 1102
in equine urine, 405
and 11 β -HSD2, 339
LC-or GC-MS, 414–423
in saliva and plasma, 405
structure, 406
suppression tests, 342, 360, 392
use in treatment, 402

- DGKL, 1184
- DHCA. *See* 3 α ,7 α -Dihydroxy-5 β -cholestanoic acid
- DHEA. *See* Dehydroepiandrosterone
- Diaphorase in enzyme assay of bile acids, 935, 936
- Diastereoisomers of bile acids, 895, 896, 899, 900
- Diaxial and diequatorial *trans*-glycol structures of bile acids, 876, 877
- Diazomethane
use in methylation of bile acids, 872, 873
- Diet and estrogens, 618
effect on increased 2-hydroxylation, 618
- Dietary supplements
presence of anabolic steroids in, 769–770
- Diethylhydrogensilyl (DEHS) ethers of bile acids, 876, 877, 911
- Diethylsilylene derivatives of bile acids, 876, 877, 890, 911
- Diethylstilbestrol, 10, 11
- Diflorasone diacetate, 1102, 1110
- Digitoxin and digitoxigenin, 39
Carbon-13 shifts in NMR, 98
proton chemical shifts of steroids, 96–97
- Dihydroergosterol, 6
- 5 α Dihydroprogesterones. *See* 5 α Pregnanediones
- 5 β Dihydroprogesterones. *See* 5 β Pregnanediones
- Dihydrotachysterol₃
formula, 984
- Dihydrotachysterols, 967, 985
- Dihydrotestosterone (5 α -DHT), 9, 10, 238, 458, 460, 466, 472, 474
androgenic activity, 458
biosynthesis, 458
formation from testosterone, 458
in prostate, 472, 474
metabolism, 492
- 5 α -Dihydrotestosterone-1-carboxyethyl thioether, 287
- Dihydroxy bile acids, 876, 879, 882, 886, 890, 891, 895, 898, 910, 930
- 26,27-Dihydroxy bile alcohols, 901
- 3 α ,12 α -Dihydroxy-5 β -cholanic acid, 12
- 3,6-Dihydroxycholanoates, 890
- 3 β ,12 β -Dihydroxy-5 β -cholanoic acid, 893
- 3 α ,19-Dihydroxy-5 β -cholanoic acid (19-hydroxy-lithocholic acid), 894
- 3 β ,7 α -Dihydroxychol-5-enoic acid, 859, 891
- 3 β ,7 β -Dihydroxychol-5-enoic acid 3-sulphate, 7-*N*-acetylglucosaminide, 932, 933
- 3 α ,7 α -Dihydroxy-5 β -cholestanoic acid (DHCA), 895, 911, 930
- 3 β ,7 α -Dihydroxy-5-cholestenoic acid, 891
- 1 α ,25-Dihydroxy-16-ene-23-yne-vitamin D₃ formula, 986
- 7 α ,12 α -Dihydroxy-3-oxochol-4-en-24-oic acid, 921, 922
- 7 α ,12 α -Dihydroxy-3-oxo-5 β -chol-1-enoic acid, 888
- 7 α ,12 α -Dihydroxy-3-oxo-4-cholestenoic acid, 887
- 3 α ,17 α -Dihydroxy-5 α -pregnan-20-one.
See Androgens
- 3 α ,21-Dihydroxy-5 β -pregnane-11,20-dione, 12
- 11 β ,21-Dihydroxypregn-4-ene-3,20-dione, 12
- 11 β , 17 α Dihydroxy-9 α -fluoro-pregn-4-ene,-3, 20-dione17-acetate. *See* Fluorogestone acetate (FGA)
- 1 α ,24S-Dihydroxyvitamin D₂
formula, 1021
identification in serum by high resolution GC-MS, 1021
- 1 α ,25-Dihydroxyvitamin D₃
binding assays for, 1015–1017
extra-renal action/formation, 975–978, 980
formula and DBP- and VDR-binding affinities, 972–3, 986
GC-MS of, 1029
immunoassays for, 1017–1018
LC-MS assay, 1032
mechanism of action, 975–978
NMR data
¹³C-NMR, 1042
¹H-NMR, 1045
renal formation, 975
scintillation proximity assay, 1018
VDRE, 977–978
- 24(R),25-Dihydroxyvitamin D₃
formation of, 973
formula and DBP- and VDR-binding affinities, 972–973
GC-MS of, 1029
LC-MS of, 1032
suggested action of, 978–979
- 26,27-F6-1 α ,25-Dihydroxyvitamin D₃
formula and use of, 979, 986
GC-MS of, 1020, 1029
- Diindolylmethane (DIM), 618
- Dimethylalkylsilyl ethers of bile acids, 874, 880
- Dimethylaminoethyl (DMAE) esters of bile acids, 930
- Dimethylethylsilyl (DMES) ethers of bile acids, 873–876, 878, 880, 908
- Dimethylethylsilylimidazol (DMESIM) in derivatisation of bile acids, 874

- Dimethyl polysiloxane phase in GC of bile acids, 875, 877
- 2,4-Dinitrophenyl hydrazine in derivatisation of bile acids, 938
- Diosgenin, 11, 12
- Carbon-13 shifts in NMR, 98
- 3,20-Dioxopregna-4,6-dien-19-yl acetate, 47
- Direct (non-extraction) immunoassays, 302–303, 310, 313
- for androgens commercial kits, 513–521, 524
- Direct probe EI–MS of bile acids, 901
- Disease-specific screening tests, 892, 895, 896, 899, 900, 911, 914, 915, 931, 933, 935, 937, 939
- Doping with ‘natural’ steroids
- 5 α -dihydrotestosterone (DHT), 813–814
 - androstenediol, 815–816
 - androstenedione, 815–816
 - boldenone, 814–815
 - DHEA, 815
 - nandrolone, 807–813
 - testosterone, 802–807
- Double side chain vitamins D
- NMR data, 1049
 - nomenclature, 1049
 - side chain conformation, 1048
- Δ^4 -3-oxosteroid 5 β -reductase deficiency in bile acid synthesis, 886, 887
- Δ^7 -reductase in bile acid biosynthesis, 892
- Dried blood spots–bile acid analysis, 910, 931
- D-ring cleavage of bile acids, 881, 883, 893
- Drostanolone, 744
- Drostanolone propionate, 1102
- Dydrogesterone, 1102, 1110
- E**
- EB1089
- formula, 986
 - LC-MS assay, 1032
- Ecalcidene
- degradation to 5Z-isovitamins D, 1052
 - side chain structure, 1044
- Ecdysone
- Carbon-13 shifts in NMR, 98
 - proton chemical shifts of steroids, 96–97
- ED-71
- formula, 986
 - LC-MS assay, 1032
- Electroanalytical methods in compendial analysis, 1132–1133
- Electrochemical detection in LC of bile acids, 938
- Electrochemical detection of estrogens, 622–626, 650, 654, 678, 680, 682, 688, 692
- Electrochemiluminescence
- in immunoassay, 296
- Electron capture atmospheric pressure chemical ionisation (ECAPCI), 125
- Electron capture detection (ECD) in GC of bile acids, 873, 878, 881, 910
- Electron-capture negative chemical ionisation (EC-NCI). *See* Electron-capture negative ionisation (ECNI)
- Electron-capture negative ion chemical ionization (NICI) in bile acid MS, 910, 912
- Electron-capture negative ionisation (ECNI), 119
- Electronic healthcare record, 1164
- Electron impact ionization (EI) in GC-MS of bile acids, 872, 879, 880, 882, 886, 887, 891, 897, 899, 901, 902, 907, 908, 910, 912
- Electron ionisation (EI)
- fragmentation
 - 5 α -androstan-17 β -ol, 138
 - 5 α -androstan-3 β -ol 3-acetate, 139
 - 5 α -androstan-17 β -ol, 137–138
 - 5 α -androstan-1-one, 140–141
 - 5 α -androstan-3-one, 141–142
 - 5 α -androstan-7-one, 142–143
 - 5 α -androstan-11-one, 142–143
 - 5 α -androstan-2-en-16-one, 144
 - 5 α -androstan-14-en-17-one, 143–144
 - 3,17 β -bistrimethylsilyloxyandrosta-3,5-diene, 135
 - cholesterol, 138
 - cholic acid triacetate, 144
 - cyclohexanone rearrangement, 140
 - 2 ξ ,3 ξ -dihalo-5 α -cholestanes, 139–140
 - 3,3-ethylenedioxy-5 α -androstan-17 β -ol, 142
 - general types, 133
- Electron ionisation (EI) (*cont.*)
- homolytic and heterolytic cleavage, 136
 - mass-to-charge ratio (*m/z*), 134
 - molecular ion, 135
 - rearrangements, 136
 - retro Diels Alder reaction, Δ^2 -steroids, 139
 - testosterone, 135
 - TMS ethers, 133–134
 - TMSO groups, 134
 - 17 β -trimethylsilyloxyandrostan-4-en-3-one, 135
 - spectra interpretation, 145–148

- Electrospray (ES), 227
 nano-ES, 240–241
- Electrospray ionization (ESI) in LC-MS of
 bile acids, 855, 866, 868, 869, 882,
 901, 902, 911, 921, 922, 923, 928,
 930, 931, 933, 934
- Elocalcitol (BXL 628), 986
 degradation to 5Z-isovitamins D, 1052
 formula, 986
 side chain structure, 1044
- Enantiomers, 2
 compendial analysis, 1126, 1135–1136,
 1139, 1146, 1151
- Enol-TMS ethers of bile acids, 874
- Ent-estradiol, 2
- Environmental estrogens, 671, 673–674, 681,
 683, 691–692, 701
 estrogen receptor assay, 701
 estrone & estradiol, 692
 ethinylestradiol, 692
 food, 648, 702
 GC & GCMS, 645–646
 hazard, 702
 immunoassays, 702
 pre-purification, 692
 river water, 622–626, 672, 683, 684, 687,
 692, 693, 702
 sensitivity, 701
 sewage, 611, 620, 622–626, 633, 683,
 691–693, 701
 waste water, 620, 628–630, 692, 696, 702
 yeast assays for estrogenicity, 701
- Enzymatic colorimetric/fluorometric assays
 for bile acids, 935–938
- Enzymatic detection of bile acids, 866, 867,
 871, 937
- Enzyme amplification technique for bile acid
 assay, 936
- Enzyme hydrolysis of bile acid conjugates,
 859, 862, 870, 901, 908, 909.
See also Hydrolysis of bile acid
 conjugates
- Enzyme immunoassay (EIA)
 for androgens, 516–521, 528–529
 for bile acids, 939
 for corticosteroids, 347, 358, 360, 376,
 379, 382, 405
 for estrogens, 668, 673, 686
 for progestogens, 568–570
 for vitamins D metabolites, 1016, 1018,
 1057–1058
- Enzymes in steroid metabolism
 cytochrome P450s, 331, 334–336
 11 β -hydroxysteroid dehydrogenases, 339
 reductases, 337
 terminology/nomenclature, vi, 334
- 3-Epi-1 α ,25-dihydroxyvitamin D₃
 proton NMR data, 1051
- 20-Epi-1 α ,25-dihydroxyvitamin D₃
 formula, 986
 side chain conformation using NMR, 1048
- Epibrassinolide, 7
- 3-Epi-25-hydroxyvitamin D₃
 effect on 25-OHD₃ assay, 1059
- Epi-testosterone excretion, 804–805
- 1 α ,21'-Epoxy-20S-methylpregnocalciferol-
 3,21-bis-O-TMSi ether dimer
¹³C-NMR data, 1042
 formula, 1041
- EPTIS, 1184
- EQA, 1155, 1167
- EQA Advisory Panels, 1168
- EQA organizer, 1167
- EQAS, 1167
- EQA Steering Committee, 1168
- Equatorial bond, 8
- Equatorial hydroxyl groups in bile acids,
 863, 870
- Equilenin (3-Hydroxy-estra-1,3,5,7,9-pentaen-
 17-one), 10, 11, 40, 681–682,
 684–685
- Equilin, 10, 11, 40, 681–685
 compendial analysis, 1102, 1150
- Equine sports
 control of steroids in, 748
 nandrolone in, 807–810
 testosterone, 807
- Ercalcidiol. *See* 25-Hydroxyvitamin D₂
- Ergocalciferol, 22, 970, 1102, 1110.
See also vitamin D₂
- Ergosterol, 6, 11, 19, 970, 984
 Carbon-13 shifts in NMR, 98
 proton chemical shifts of steroids, 96–97
- Estetrol. *See* 15 α -Hydroxyestriol
- Estradiol
 benzoate, 1102, 1118
 bioactivity assays, 669–670
 breast tissue precursors, 673
 cancer risk, 616, 619
 Carbon-13 shifts in NMR, 98
 proton chemical shifts of steroids, 96–97
 chemistry of, 1, 10, 226, 230, 239,
 children, 647, 654–656–658, 670
 compendial analysis of, 1102, 1110, 1112,
 1118–1120, 1122, 1124, 1125,
 1127, 1134, 1136, 1141, 1142,
 1144, 1146, 1147, 1149, 1150, 1152
 concentration (plasma), 653–655

- concentration (saliva), 667, 668
- cyclodextrin assisted extraction, 178
- cypionate, 1102, 1110
- detection limits, 621
- exercise, 618
- extraction by MIP, 183
- HPV, 619
- in human plasma by GC-MS, 183
- intracrine production, 611–614
- LC of, 210–219
- LC-MS/MS, 236, 249
- mechanism of action, 614–616
- neuroactive estradiol, 669
- non-protein bound estradiol, 655, 667
- in pharmaceutical preparations, 195
- physiology, 616
- saliva assays, 655, 667
- sensitivity, 666
- separation on Celite, 185
- separation on graphitised carbon, 179
- solvent separation from estriol, 173
- synthesis, 606
- use of MEKC, 183
- use of stir bars, 179–180
- valerate, 1102, 1110, 1112, 1142
- (±)-Estradiol, 2
- Estradiol measurement by immunoassay, 302–305, 309, 317
- Estradiol-6-O-(carboxymethyl)oxime, 287
- 17 β -Estradiol. *See* Estradiol
- 17 α -Estradiol assays, 649, 670–671
- environmental assays, 671
- 17 α -estradiol in brain, 671
- GC-MS assays, 671
- LC-MS assays, 670–671
- neuroprotective properties, 671
- Estranes, 1
- Estra-1,3,5(10)-trien-16 α ,17 β -diol, 10
- Estra-1,3,5(10)-trien-3,17 β -diol, 10, 33
- Estriol, 10, 239, 1102, 1118
- assay methods, 622–626, 632, 637, 645, 648, 652, 656–658–665, 674–676, 693
- saliva assay problems, 675
- serum/plasma levels, 650, 675
- sources, 674
- synthesis, 675
- urine, 622–626, 632
- Estriol 16-glucuronide, 686
- amniotic fluid, 652
- Estrogen, 605
- in children, 639, 647, 654, 655, 657, 670, 702
- Estrogen analysis
- bioluminescence assays, 641
- column chromatography, 633–635
- enzyme labeled assays, 641
- estrogen responsive luciferase reporter, 670
- extraction, 620–627
- GC-MS reference method, 670
- HeLa cell assay, 669
- immunoassays, 620, 621, 632, 636–641, 643–645
- interference in immunoassays, 631, 642–645
- LC, 649–650
- MS assays
- GC-MS & MS/MS, 645–649, 656–659
- LC-MS & MS/MS, 649–652, 659–665
- novel assays, 639, 641
- purification of estrogens, 619
- quantitation, 622–626, 628–630, 632–636
- separation, 627, 632–635, 637, 645, 651, 672, 679, 681, 689
- ultrasensitive assays, 617, 683, 691
- yeast enhanced green fluorescent protein assay (YEGFP), 669
- Estrogen conjugates, esters, 605, 628–630, 683
- assay of intact conjugates, 683, 685
- assays with prior enzyme step, 684–685
- assays with prior solvolysis, 683–684
- estriol 16-glucuronide, 686
- immunoassay, 685–686
- LC-MS/MS assays, 687
- pig, 628–630
- Estrogen receptors, 611, 614–615, 669, 701
- Estrogens, conjugated,
- compendial analysis, 1102, 1108, 1110, 1118, 1149, 1150
- Estrogens, esterified,
- compendial analysis, 1102, 1108, 1110
- Estrone, 10, 239
- compendial analysis, 1102, 1110, 1118, 1120, 1136
- Estrone and estrone conjugate assays, 671–674
- Estrone assays, 640, 656–658–665, 671–676, 693
- immunoassays, 671
- LC-MS and GC-MS assays, 673
- Estrone glucuronide, 673
- Estrone sulfate assays, 673
- estrone-estradiol inter-conversion, 674
- estrone sulfate and glucuronide assays, 673
- estrone sulfate as source of estradiol, 673
- estrone sulfate concentration (men), 674
- menopause, 613
- Estropipate, 1102, 1110

- Ethinylestradiol, 19, 20, 619, 681–683
 adducts from 4-OH derivatives, 681
 assays, 623, 681
 catechol derivatives, 681
 cattle hair, 622–626, 656–658, 682
 compendial analysis, 1102, 1110, 1112, 1114, 1116, 1118–1122, 1127, 1129, 1135, 1136, 1140, 1141, 1149, 1151
 DNA damage and cancer risk, 681
 dog, 682
 environmental assays, 691–702
 ethinylestradiol assays, 623, 628–630, 647, 682, 683
 GC-MS and LC-MS assays, 682
 immunoassays, 682
 novel, 682
 formation, 681
 GC-MS and LC-MS assays for EQs, 682
 immunoassays for the EQs, 682, 685
 metabolism, 681
 monkey, 623, 659–665, 682, 685
- Ethyl ester-methyloxime-dimethylethylsilyl ether (Et-MO-DMES) derivative of mono-oxo bile acids, 878
- Ethyl esters of bile acids, 874, 878, 896, 910
- Ethylestrenol
 metabolism, 761
- Ethinodiol diacetate,
 compendial analysis, 1102, 1110, 1133, 1140
- 17 α -Ethinyl-17 β -hydroxy-4-estren-3-one. *See* Norethisterone (NE)
- 17 α -Ethinyl-17 β -hydroxy-18-homoandrosta-4,9,11-trien-3-one. *See* Gestrinone
- Ethinylestradiol. *See* Ethinylestradiol
- 17 α -Ethinyl-13-ethyl-17 β -hydroxy-gona-4,15-dien-3-one. *See* Gestodene
- Etianic acids, 841, 881
- Etiocholane, 13
- European Pharmacopoeia (Ph. Eur.). *See* Pharmacopoeias
- European Union, 1159
- Evaporative light-scattering mass detector (ELSD) for LC of bile acids, 869
- External quality assessment, 1155, 1167
 of immunoassays, 311, 313–314
- Extraction, 168–184
 graphitised carbon black, 179
 immunoaffinity, 182–183
 before immunoassay, 173
 solid-phase (SPE), 174–180
 solvents, 169–174
 SPE sorbents, 176
 stir bars, 179
 use of molecularly imprinted polymers (MAP), 183–184
 use of restricted access material (RAM), 183–184
- Extraction of bile acids, 847–853
- F**
- FAB-CID of bile acids, 913, 914, 922, 932
- FAB-MS of bile acids, 867, 882, 899, 901, 902, 913–914, 921
- Fast atom bombardment (FAB) ionisation, 119–120
- Fertility
 treatment monitoring, 642, 645
- Fibroblast-like growth factor (FGF-23).
See Phosphatonin hormone
- Finasteride
 compendial analysis, 1102, 1110, 1115, 1118, 1122, 1124, 1126, 1141, 1142, 1148
- Fischer projection, 4, 6
- Flame ionization detector (FID) in GC of bile acids, 872, 878, 881, 907
- Flow-injection analysis, 1113, 1117, 1142, 1153
- Fludrocortisone acetate, 1102, 1110
- Flumetasone pivalate, 1102, 1111
- Flunisolide, 1102, 1110, 1115, 1140
- Fluocinolone acetonide, 1103, 1110, 1115, 1140
- Fluocinonide, 1103, 1110, 1123
- Fluocortolone pivalate, 1103
- Fluorescein isothiocyanate, 299
- Fluorescence derivatives in LC of bile acids, 870, 872
- Fluorescence detection in LC of bile acids, 845, 870, 873, 935, 937, 938
- Fluorescence in immunoassay
 europium-labelled oestradiol conjugate, 300–301
 fluorophores, 299
 lifetime, 298–299
 sensitivity, 299
 stoke's shift, 299
 time-resolved, 300, 306
- Fluorimetric methods for bile acids, 936
- Fluorimetry, 1114, 1115, 1127, 1137
- Fluorine (¹⁹F) NMR, 83–84
- Fluorogestone acetate (FGA), 591
- Fluorometholone, 1103, 1110
- Fluoxymesterone, 744, 1103, 1110, 1116
 metabolism in the horse, 761

- Flurandrenolide, 1103, 1110
- Fluticasone
 LC-or GC-MS, 414–423
 structure, 406
- Fluticasone propionate, 1103, 1114, 1115, 1122, 1132, 1133, 1148, 1152
- Foetal bile acids, 847, 911
- Formate esters of bile acids, 902
- Formazan colorimetry during bile acid enzyme assay, 936
- Fourier transform ion cyclotron resonance (FTICR), 129
- Fragmentation of bile acids by EI, 880–882, 902–906
- Fragment ion recording during MS of bile acids, 884, 885
- Free induction decay (FID), 66
- Free steroids. *See* Unbound steroids
- Free testosterone measurement, 319
- Freudenberg's Rule of Shift, 42
- Furazabol, 744
- Fused silica capillary columns in GC
 of bile acids, 874, 875
- G**
- β -Galactosidase as labels in EIA
 of bile acids, 939
- Galactosides, 845, 861, 923
- Gas chromatography/combustion/isotope ratio MS (GC/C/IRMS), 816–821
 equipment schematic, 816
- Gas chromatography (GC), 198–204
 columns, 198–200
 in compendial analysis, 1099, 1108, 1110, 1121, 1138, 1143, 1145, 1147, 1149, 1153
 derivatisation, 201–202
 detectors, 202–204
 injection, 200–201
 mass spectrometry (GC-MS), 245
 of vitamin D metabolites/analogs
 B-ring closure during GC, 1024–1025
 characterisation of metabolites by GC-MS, 1064–1065
 cyclic boronates, 1027–1028
 dehydration, 1020, 1025–1026
 derivatisation for, 1025–1031
 formation of isotachysterols, 1007, 1025
 pyro-and isopyro-isomers, 1024
 trimethylsilyl ethers, 1026–1027
- Gas chromatography-mass spectrometry (GC-MS), 245–252, 306, 311
 of anabolic steroids
 mass spectrometry, 785–788
 sample preparation, 781–783
 trimethylsilylation, 783–785
 in urine analysis, 781–788
 of androgens, 480–500
 apparatus/scanning, 247
 of bile acids, 878–913
 in compendial analysis, 1021, 1024, 1034, 1099
 of corticosteroids, 349, 356–357, 362–373
 of estrogens 645–649, 656–658
 internal/external standards, 248
 of progestagens, 573–574
 quantitation, 248
 sample preparation, 245–247
 of vitamins D metabolites, 1023–1031
- Gastric contents–bile acids, 869, 884
- Gauche conformation, 8
- GC analysis of bile acids, 874–876, 912
- GC-MS of bile acids, 858, 879, 881, 901, 902, 907, 908, 911, 912, 921
- GC-MS profile(s) of bile acids, 856, 884, 885, 889, 893, 898, 901, 909
- Gc protein. *See* Vitamin D binding protein
- Gemini. *See* Double side chain vitamins D
- Generalised Karplus relationship, 79
- Genetic defects in bile acid synthesis, 842, 892, 895, 896, 914, 915, 931
- Gestodene, 591
- Gestrinone, 61
 Carbon-13 shifts in NMR, 98
 proton chemical shifts of steroids, 96–97
 metabolism, 791
 structure, 755
- Glassware, steroid binding to, 170
- GLTM. *See* Grouped Laboratory Trimmed Mean
- Glucocorticoid remediable aldosteronism (GRA), 233, 377, 385, 403. *See also* Primary hyperaldosteronism
- Glucocorticoids, 11
 analysis of, 357–384
 biological activity, 332–333
 definition, 330
- Glucosiduronic acids, 18
- Glucuronidases for hydrolysis of bile acid glucuronides, 861
- Glucuronides, 18. *See also* Androgens
- Glucuronides of anabolic steroids
 hydrolysis of, 781–783
 nomenclature, 772
- Glycocholic acid, 18

- Glycol cleavage in MS of bile acids, 898
- Glycolithocholic acid 3-sulphate, 939
- Glycosidases in analyses of bile acid glycosides, 861, 939
- Glycosides, 861, 878, 884, 926. *See also* Bile acid glucosides; Galactosides; Glucuronides; *N*-acetylglucosaminides
- Gonanes, 1
- Gradient elution during LC of bile acids, 867, 869
- Graphic equaliser plots, 1173
- Grouped Laboratory Trimmed Mean (GLTM), 1172
- Guthrie card
 - analysis of bile acids in blood spots, 930, 931
 - analysis of corticosteroids in blood spots, 380
 - analysis of 25-OHD in blood spots, 1054
- Gynecomastia, 609
- H**
- Hair
 - anabolic steroids in, 778–781
 - androgens in, 497–499
 - HPLC-RIA in, 499
- Halcinonide, 1103, 1110, 1123
- Hammarsten's α - and β -phocaecholic acids, 898, 899
- Hapten-enzyme conjugate in IA of bile acids, 939
- Hapten in IA of bile acids, 938, 939
- Haptens, 565
- Haptens, 283, 285, 286
- Hepatobiliary disease, 842–844, 846, 855, 870, 872, 883, 886, 887, 889, 891, 892, 895, 896, 913, 914, 918, 921, 932, 934, 938, 939
- Hexafluoroisopropyl ester-trifluoroacetyl derivatives of bile acids, 873, 909
- High performance liquid chromatography (HPLC). *See* Liquid chromatography (LC)
- High-performance thin-layer chromatography (HPTLC). *See* Thin-layer chromatography (TLC)
- High Resolution GC-MS (GC/HRMS), 785–788
 - detection of low levels of nandrolone in men, 810
- High turbulence liquid chromatography (HTLC), 231
- Hindered hydroxyl groups in bile acids, 870, 873, 877
- Holarrhimine, 23
- Homo(C₂₅)-bile acids, 859, 881, 895
- Homologs—as internal standards for bile acid assay, 908
- Horseradish peroxidase in immunoassay, 295, 298
- Host-guest complexes of bile acids with cyclodextrin, 868–869
- HPLC retention factor/behaviour of bile acids, 862–872
- HPV and estrogens, 617–619
- 11 β -HSD. *See* 11 β -Hydroxysteroid dehydrogenase
- [²H₅]trimethylsilyl (TMS) ethers of bile acids, 882
- Hydrogen-deuterium exchange of labeled bile acids, 909
- 5 α / β -Hydrogen in bile acids, 879, 883
- Hydrolysis of bile acid conjugates, 858–861, 891, 898, 908, 909. *See also* Alkaline hydrolysis of conjugated bile acids; Solvolysis of bile acid conjugates; Glucuronidases for hydrolysis of bile acid glucuronides
- Hydrolysis of steroid conjugates, 180–182
- Hydrophobic surface/region/area in bile acid LC, 865, 866
- Hydroxyalkyl Sephadex LH-20 in bile acid separation, 851–852
- 17 β -Hydroxyandrosta-4,6-dien-3-one, 16
- 3 α -Hydroxy-5 α -androstan-17-one, 52
- 3 β -Hydroxy-5 α -androstan-16-one, 52
- 17 β -Hydroxy-5 α -androstan-3-one, 10
- 3 α -Hydroxyandrost-5-en-17 β -yl acetate, 17
- 3 β -Hydroxyandrost-5-en-17-one, 3, 10
- 17 β -Hydroxyandrost-4-en-3-one, 10
- 4-Hydroxy bile acids, 872, 877, 889, 911
- 5-Hydroxy bile acids, 889
- 6-Hydroxy bile acids, 877, 889, 890, 910–911, 938
- 12-Hydroxy bile acids, 863, 865, 869, 887, 891–893, 937
- 15-Hydroxy bile acids, 893
- 16-Hydroxy bile acids, 893, 894
- 21-Hydroxy bile acids, 897
- 22-Hydroxy bile acids, 897
- 23-Hydroxy bile acids, 898, 899
- 1 β -Hydroxy bile acids, 883, 884, 889, 910–911, 938
- 2 β -Hydroxy bile acids, 872, 884, 889

- 22-Hydroxy bile alcohols, 896, 897
23-Hydroxy bile alcohols, 896
24-Hydroxy bile alcohols, 896
25-Hydroxy bile alcohols, 896
27-Hydroxy bile alcohols, 896
24-Hydroxy-C₂₇-bile acids, 899, 900
25-Hydroxy-C₂₇-bile acids, 900–901
26-Hydroxy-C₂₇-bile acids, 901
22-Hydroxy-chenodeoxycholic acid
(*(22S)*3 α ,7 α ,22-trihydroxy-5 β -cholanoic acid), 897
3 α -Hydroxy-6-cholenoic acid, 891
3 β -Hydroxy-5-cholenoic acid, 886, 938
5-Hydroxy-5 α -cholestan-6-one, 57
5-Hydroxy-5 β -cholestan-6-one, 58
3 β -Hydroxycholest-5,7-dienoic acid, 892
3 β -Hydroxycholest-5,8-dienoic acid, 892
3 β -Hydroxy-5-cholestenic acid, 886, 891
7 α -Hydroxycholest-4-en-3-one, 931
7 α -Hydroxycholesterol, 891
24*S*-Hydroxycholesterol-3-sulphate,
24-glucuronide, 921
18-Hydroxycorticosterone
in differential diagnosis of
hyperaldosteronism, 391
structure, 331
6 β -Hydroxycortisol
analysis of, 383–384
urinary excretion, 338
18-Hydroxycortisol
immunoassay, 346
synthesis, 333
3 β -Hydroxy- Δ^5 -C₂₇-steroid oxidoreductase
(HSD3B7), 858, 891, 915
16 α -Hydroxy-dehydroepiandrosterone, 680
7 α -Hydroxy-DHEA, 493, 502
17 β -Hydroxy-11 β -[4-dimethylaminophenyl]-
17 α -[propynyl]-estra-4,9-dien-3-
one. *See* Mifepristone
3-Hydroxyestra-1,3,5(10)-trien-17-one, 10
15 α -Hydroxyestriol (Estetrol), 631, 650,
679–681
assays, 679
concentration (pregnancy), 679
LC-MS assays, 680
novel assays, 680
radioimmunoassays, 679
synthesis during pregnancy, 679
16 α -Hydroxyestrone, 617, 619, 622–626, 677
Heyns rearrangement, 611, 613
2-hydroxy/16-hydroxyestrone ratio,
617–618
breast cancer risk, 618
prostate cancer risk, 618
16 α -OHE1 adducts, 611
1 α -Hydroxy-20*S*-formyl-pregnacaliferol-
bis-O-TMSi ether
¹³C-NMR data, 1042
7 β -Hydroxy isomers of bile acids, 863, 870,
871, 875, 877, 891, 898, 936
2,3-Hydroxylated bile acids, 884, 890
3,4-Hydroxylated bile acids, 876, 890
Hydroxylation, 11
Hydroxylation of bile acids, 841, 846, 847
25-Hydroxylation of vitamin D₃ identification
as CYP27A1, 974
7 α -Hydroxyl group in bile acids, 865, 891, 936
3 α -Hydroxyl group of bile acids, 870, 871,
935, 936
3 β -Hydroxyl group of bile acids, 863, 870, 938
17-Hydroxy-6 α -methyl-pregn-4-ene-
3,20-dione 17-acetate. *See*
Medroxyprogesterone acetate
3 α -Hydroxy-12-oxo-5 β -cholanoic acid, 893
7 α -Hydroxy-3-oxochol-4-en-24-oiic acid, 887,
921, 922
7 α -Hydroxy-3-oxo-4-cholestenic acid,
887, 888
6 α -Hydroxy-3-oxo structures of bile acids, 887
7 α -Hydroxy-3-oxo structure of bile acids, 877,
887, 892
3 β -Hydroxypregna-5,16-dien-20-one, 11, 12
3 α -Hydroxy-5 α -pregnane-11, 20-dione. *See*
Alphaxolone
3 α -Hydroxy-5 α -pregnane-11, 20-dione-21
acetate. *See* Alphadolone acetate
3 α -Hydroxy-5 α -pregnan-20-one, 3, 4
3 α -Hydroxy-5 β -pregnan-20-one, 4
21-Hydroxy-pregn-4-ene-3,20-dione, 12
17-Hydroxypregn-4-ene-3,11,20-trione, 12
17-Hydroxypregnenolone
analysis of, 381–382
structure, 331
17-Hydroxyprogesterone, 182, 232–233
analysis of, 378–380
in body fluids, 341
enhancement of ionisation
in LC-MS/MS, 229
excess in CAH, 378–380
GC-and LC-MS of, 371–373
17-Hydroxyprogesterone (*cont.*)
LC-MS/MS, 173–233
non-extraction IA, 173
separation on LH-20 column, 190
in serum/saliva, 226, 234
structure, 331
18-Hydroxyprogesterone, 61

- Hydroxyprogesterone and caproate, 1103, 1124, 1147
- 2-Hydroxypropyl- β -cyclodextrin in bile acid separation, 869
- 11 β -Hydroxysteroid dehydrogenase
in cortisol/cortisone conversion, 333, 337, 339, 377, 398
- Hydroxysteroid dehydrogenases in enzyme assay of bile acids
- 3 α -hydroxysteroid dehydrogenase (3 α -HSD), 867, 871, 935–938
 - 3 β -HSD, 936–938
 - 7 α -HSD, 936, 937
 - 7 β -HSD, 936, 937
 - 12 α -HSD, 936, 937
- 3 β -Hydroxysterol- Δ^7 -reductase, deficiency in Smith-Lemli-Opitz syndrome, 892
- 3 β -Hydroxy-estra- Δ^5 structure of bile acids, 886
- 15 α -Hydroxytestosterone, 494–495
- 3-Hydroxy-estra-1,3,5(10),7-tetraen-17-one, 10
- 22-Hydroxy-ursodeoxycholic acid, 898
- 1 α -Hydroxyvitamin D₂
¹³C-NMR data, 1042
formula, 984
- 1 α -Hydroxyvitamin D₃
¹³C-NMR data, 1042
5E-, bis-O-TBDMSi-derivative of, 1042
formula, 984
GC-MS of metabolites of, 1062–3
LC-MS assay, 1032
- 1 α -Hydroxyvitamin D₅
¹³C-NMR data, 1042
formula, 984
- 25-Hydroxyvitamin D₂ (25-OHD₂)
commercial immunoassays for, 1057–1058
conversion factors for concentration units for 25-OHDs, 969
GC-MS of, 1029
LC-MS assay, 1032
- 25-Hydroxyvitamin D₃ (25-OHD₃)
analysis in blood, 968, 1054–1059
commercial immunoassays for, 1057–1058
in dried blood spots, 1054
effect of 3-epi-25-OHD₃, 1059
conversion factors for concentration units for 25-OHDs, 969
extended half-life, 974
external QA for (DEQAS), 1056, 1059, 1183
formula, 972
GC-MS of, 1029
LC-MS of, 1032
- as means of assessing vitamin D status-desirable concentrations, 1054–9
- MS of dehydrated derivative, 1020
- MS of mixed ether derivative, 1023
- MS of trimethylsilyl ethers, 1023
- MS of underivatized, 1022
- 25(S)-Hydroxy-vitamin D₃-26,23-lactone formation from 25-OHD₃, 983
formula and DBP- and VDR-binding affinities, 972–973
- Hyochoic acid, 860, 889, 890
- Hyodeoxycholic acid, 902, 920, 930, 1122
- Hypsochromic effect, 32
- ## I
- ID-GCMS, 1172, 1180
- ILAC, 1168
- Immobilized 3 α -HSD in bile acid assay, 871, 938
- Immunoassay
antibody
affinity and avidity, 290
antibody titer, 289–290
bridge recognition problems, 291–292
cross-reaction, 292–293
haptens, 285
immunization protocols, 286–287
immunogen production, 286
immunoglobulins, 284–285
kinetics, 283–284
monoclonal antibody production, 287–288
saturation analysis, methods, 288
screening assay, 289
specificity, 291
androgens, 511–538
automated IA systems, 354–355
for bile acids, 938–940
calibration curves, 310
correlation, methods, 314
corticosteroids, 346–355
epitopes, 285
equilibrium/affinity constant (K_a), 284
estrogens, 620, 621, 632, 636–644
external quality assurance, 314–315
fluoro-immuno assay (FIA), 42
free (unbound) steroids, assays, 319–320
immunometric assays, 315–317
imprecision, 308–309
inaccuracy, 311
interference
binding proteins, 313
blood collection tube, 312

- cross-reactions, 313
- extraction, 312
- heterophilic antibodies, 313
- matrix effects, 314
- microarrays, 317–319
- miscellaneous controls, 314
- plasma resonance biosensors, 320–321
- progestagens, 564–573
- radio-immuno assay (RIA), 42
- radioisotopes, 293–294
- recovery and bias, 310
- sensitivity, 310
- separation methods, 307–308
- validation, 308–314
- vitamins D metabolites, 1015–1018, 1057–1058
- Immunoassay design, 1162
- Immunoassay standardisation, 1159
- Imprecision, 1157, 1162, 1164
- Impurities in bile acid assay, 878. *See also*
 - Artifacts (artefacts) formed during bile acid assay
- Impurity profile
 - in compendial analysis, 1099, 1108, 1117, 1119, 1133, 1134, 1136, 1137, 1139, 1140, 1144
- Infrared absorption spectroscopy
 - 5 α -androstan-16-one, 52
 - 5 α -androstan-17-one, 52
 - aldehydes, 60–61
 - carboxylic acids and derivatives, 62
 - fingerprint region, 52
 - gestrinone, 59
 - hydrocarbon skeleton, 53–54
 - hydroxyl/carbonyl interactions, 61–62
 - hydroxyl groups, 56–58
 - 18-hydroxyprogesterone, 61
 - instrumentation, 51–52
 - ketones, 58–60
 - sample preparation, 49–50
 - solvent effects, 60
 - solvents, 49
 - unsaturation, 54–56
 - vibration modes, methylene groups, 48
 - wave number and frequency, 48
- Injection, injectable, 1109–1112, 1122, 1141, 1149, 1153
- Institute for Reference Materials and Measurements (IRMM), 1160
- Interference, 1180
- Internal standards, 166–169
 - addition to sample matrix, 167
 - in analysis of vitamins D and metabolites, 998–1000
 - for bile acid assay, 847, 848, 907–909, 912, 923, 925
 - deuterated standards, source of, 168
- International Olympic Committee (IOC).
 - See* WADA
- International Standards Organisation (ISO), 1168
 - ISO protocols, 1156, 1168
- Internal Quality Control (IQC), 1164
- Intestinal bacterial 7 α -dehydroxylation of bile acids, 842, 891
- Intestinal bacterial metabolism of bile acids, 841, 842, 847, 884, 886
- Intestinal fluid–recovery of bile acids/lipids from, 851, 898, 937
- Intestinal obstruction, 884
- Intrahepatic cholestasis of pregnancy, 855–856, 889, 938
- Intramolecular hydrogen bond in deoxycholic acid, 865
- In Vitro* Diagnostics Devices
 - Directive, 1159
- Iodonitrotetrazolium in enzyme assays of bile acids, 936
- Ion exchange chromatography of bile acids, 853–857, 908, 934
- Ionization energy and potential in GC-MS of bile acids, 879, 880, 883
- Ion pair chromatography, 221–222
- Ion-pair chromatography of bile acids, 857, 868
- Ion-pair extraction of bile acids, 849, 852
- IQC. *See* Internal Quality Control
- IR (infrared) spectroscopy
 - in compendial analysis, 1100, 1111, 1114, 1137, 1140, 1142, 1149, 1150, 11115
- IRMM. *See* Institute for Reference Materials and Measurements
- Isofluprednone acetate, 1103, 1110
- Isomers–of bile acids, 872, 874, 875, 877, 883, 884, 887, 889, 890, 892, 893, 895, 896, 900, 901, 914, 917, 923, 928, 937
- Isotachysterols
 - formation, 1007, 1025
- Isotope dilution gas chromatography mass spectrometry (ID-GC-MS), 1159, 1172
- Isotopic effects during GC separation of bile acids, 909
- 5Z-Isovitamins D
 - identification by NMR as degradation products, 1052

J

Japanese Pharmacopoeia (Ph. Jp.).

See Pharmacopoeias

JCTLM. *See* Joint Committee for Traceability in Laboratory Medicine

Joint Committee for Traceability in Laboratory Medicine (JCTLM), 1159

K

Kendall's compound A, 13

Kendall's compound E, 13

Kendall's compound F, 13

Ketonic bile acids, 841, 857–858, 863–864.

See also Oxo bile acids

KH 1060

metabolite identification by NMR, 1052

NMR data, 1050

L

Labquality, 1184

Lactone formation of bile acids, 855, 894, 897, 899

LC methods for bile acids, 855, 866–871, 898

LC-MS of bile acids, 855, 866, 878, 879, 922, 923, 930, 932, 937

Levonorgestrel, 1103, 1110, 1112, 1117, 1122, 1127, 1129, 1133, 1135, 1136, 1140, 1143, 1144, 1146, 1147

Lexacalcitol. *See* KH1060

Lipidex for bile acid separation, 851, 852, 857, 898

Lipoidal esters of estradiol, 690–691
assay, 690

potency, 690

synthesis, 690

tumorigenicity, 690

Liquid chromatography (LC), 204–226

advantages of, 204

capillary-LC, 227–228

columns, 205–219

column switching, 226

in compendial analysis, 1098–1100, 1114, 1116–1119, 1121–1127, 1129, 1130, 1132–1153

steroid concentrations in human serum by, 234–236

derivatisation, 207–219, 228–231

detection, 204, 207–219, 222–224

diode array, 204, 224

identification, 224–225

injection, 222

methodology, 207–219

mobile phases, 206, 220–222

quantitation, 225–226

separation of free and glycine conjugated bile acids, 220

of vitamins D metabolites, 1000–1015

Liquid chromatography-mass spectrometry (LC-MS & MS/MS), 227–245

aldosterone, 238

of $1\alpha,25(\text{OH})_2\text{D}_3$, 1034

metabolites, 1031–1032, 1036, 1039, 1064–1065

using APPI, 1038–1039

of androgens, 480–509

androstenedione, 239

of bile acids, 855, 866, 878, 879, 922, 923, 930, 932, 937

in compendial analysis, 227–245, 1099, 1122–1124, 1127, 1135, 1138, 1140, 1148, 1149, 1151, 1153

concentrations in serum, 234–236

of corticosteroids, 362–373

adducts, 361, 389

APPI/APCI, 361

11-deoxycortisol, 238

21-deoxycortisol, 233

derivatisation, 228–231

dansyl chloride, 230

girard hydrazone, 229–230

2-hydrazine-1-methyl pyridine, 230

oximes, 230

of designer steroids, 791–792

DHEA/DHEA sulphate, 239

and diode array detection (DAD), 377

estrogens, 649–652, 659–666, 678

in cattle, 671

estrone/estradiol, 238

history of application in sport, 788–789

17-hydroxyprogesterone, 232

of intact anabolic steroid conjugates, 793–795

interfaces, 227–228

MRM, 234–236

neurosteroids, 239

of phase I & II anabolic steroid metabolites, 790–795

profiles, 238

of progestagens, 574–575

steroid sulfates, 242–243

ultra-performance liquid chromatography (UPLC)

in compendial analysis, 1124, 1125, 1138, 1149

in MS/MS of anabolic steroids, 795

in MS/MS of androgens, 491

- in MS/MS of bile acids
 - in MS/MS of estrogens, 663–664, 685, 688, 702
 - in MS/MS of vitamins D and metabolites, 1032, 1035, 1038
 - in MS/MS of xenobiotic steroids, 412–414, 424
 - vitamins D metabolites, 1031–1039
 - Liquid–liquid extraction, 469–470
 - Lithium aluminium hydride (LiAlH₄)
 - reduction of bile acids, 897, 901
 - Lithocholic acid 3-glucuronide, 909
 - Lithocholic acid (LCA), 867, 875, 884, 891, 894, 909, 939
 - Lithocholic acid-protein conjugates, 843
 - Liver (tissue) homogenates–bile acids in, 870, 892, 910
 - Long chain (C₂₇) bile acids, 860, 880, 892, 895, 899–901, 911, 930, 931
- M**
- Macroscopic magnetisation, 66
 - Madol, 747, 752
 - Magnetic properties of nuclei, 64
 - Magnetic sector instruments
 - for bile acid MS, 907
 - Magnetogyric ratio, 66
 - MALDI. *See* Matrix-assisted laser desorption/ionisation
 - Mass discrimination during bile acid MS, 883
 - Mass fragmentography, 907
 - Mass screening, 937
 - Mass spectrometric resolution
 - of bile acids, 907
 - Mass spectrometry, 117–148, 226–252, 1099, 1116, 1133, 1141, 1145, 1147
 - atmospheric pressure ionisation in LC
 - APCI, 123–125
 - APPI, 125–126
 - ECAPCI, 125
 - electrospray (ES), 121, 123
 - low-flow-rate ES, 121
 - micro-ES, 121, 123
 - nano-ES, 121, 123
 - thermospray (TS), 123
 - detector, 1099, 1121–1127, 1132, 1134, 1135, 1137–1143, 1145–1151, 1153
 - EI fragmentation
 - 5 α -androstan-17 β -ol, 138
 - 5 α -androstan-3 β -ol, 3-acetate, 139
 - 5 α -androstan-3-one, 137–138
 - 5 α -androstan-1-one, 140–141
 - 5 α -androstan-3-one, 141–142
 - 5 α -androstan-7-one, 142–143
 - 5 α -androstan-11-one, 142–143
 - 5 α -androstan-2-en-16-one, 144
 - 5 α -androstan-14-en-17-one, 143–144
 - 3,17 β -bistrimethylsilyloxyandrosta-3,5-diene, 135
 - cholesterol, 138
 - cholic acid triacetate, 144
 - cyclohexanone rearrangement, 140
 - derivatisation, 132–134
 - 2 ξ ,3 ξ -dihalo-5 α -cholestanes, 139–140
 - 3,3-ethylenedioxy-5 α -androstan-14-ene, 142
 - fragment ion or loss, 146, 147
 - general types, 133
 - homolytic and heterolytic cleavage, 136
 - mass-to-charge ratio (m/z), 134
 - molecular ion, 135
 - rearrangements, 136
 - retro Diels Alder reaction,
 - Δ^2 -steroids, 139
 - spectra interpretation, 145–148
 - testosterone, 135
 - TMS ethers, 133–134
 - TMSO groups, 134
 - 17 β -trimethylsilyloxyandrost-4-en-3-one, 135
 - electron impact mass spectra, 131–133
 - GC-MS, 245–252, 1022–1031
 - high energy MS/MS, 242
 - high resolution GC-MS, 1020, 1021
 - ionisation under vacuum
 - chemical ionisation (CI), 118–119
 - electron capture negative ionisation (ECNI), 119
 - electron ionisation (EI), 118
 - FAB ionisation and LSIMS, 119–120
 - MALDI, 120
 - LC-MS, 227–245, 1031–1039
 - mass analysers
 - FTICR, 129
 - magnetic-sector analysers, 126–127
 - orbitrap-analyser, 128
 - quadrupole ion-trap, 127
- Mass spectrometry (*cont.*)
- quadrupole mass filters, 127
 - time-of-flight analysers, 128–129
 - mass-to-charge ratio (m/z), 117
 - tandem mass spectrometry, 129–131
 - high collision-energy, 129
 - low collision-energy, 129
 - multiple reaction monitoring (MRM), 130
 - neutral-loss scan, 130
 - precursor-ion scan, 130
 - product-ion scan, 130

- Mass-to-charge ratio (*m/z*), 117, 134
- Matrix-assisted laser desorption/ionisation (MALDI), 120
in bile acid analysis, 923
- Matrix effects, 1161
- Mazipredone, 1134, 1135, 1143
- MB 15.766 (inhibitor of Δ^7 -reductase), 892
- MC903. *See* Calcipotriol
- McLafferty rearrangement during bile acid MS, 893
- Measurand, 1158
- Medroxyprogesterone acetate, 16, 17, 591–592, 1103, 1110, 1112, 1115, 1122, 1134, 1141, 1142, 1152
- Megalin, 975, 977, 980
- Megestrol acetate, 1103, 1110, 1122, 1142
- Melengestrol acetate, 1104
- Menopause
estrone sulfate in, 613
- Mepitiostane, 1104
- Meprednisone, 1104
- Mestanolone, 744
metabolism in the horse, 761
- Mesterolone, 744, 1104
metabolism in the horse, 762
- Mestranol, 1104, 1110
- Metabolomics/metabolic profiling of bile acids, 855, 875, 876, 879, 884, 885, 889, 896, 902, 912, 913, 935
- Metenolone acetate, 1104
- Metenolone enanthate, 1104
- Methandienone (methandrostenolone), 744, 757
epimerization of 17 α -sulfate, 767
metabolic demethylation, 766
metabolism in the horse, 762
- Methenolone (metenolone), 744
metabolism of acetate ester in the horse, 762
- Methods of immunoassay
bioluminescence, 296
chemiluminescence, 295–298
enzyme immunoassay, 295, 298
fluorescence, 298–300, 306, 317
microarrays, 317–319
radioimmunoassay, 283, 291, 293–294
- Methoxyammonium chloride in formation of bile acid methylloximes, 874
- Methoxy group in bile acid MS, 887, 896
- 3-Methoxyloxime in bile acid MS, 877
- m*-Methoxyphenacyl bromide in formation of bile acid derivatives during LC, 869
- 1-Methoxyphenazinemethosulphate in bile acid enzyme assay, 935
- 2-Methylacyl racemase, mutations of, 895, 915
- Methylation of estrogens, 611, 660
- Methylation (methyl ester) of bile acids, 860, 872–873
- Methyl bisnorcholanoates, 881
- Methyl cholanoates, 880, 881, 883
- 1,2 α -Methylene-6-chloro-pregna-4,6-diene-3,20 dione 17-acetate.
See Cyproterone acetate
- 2-Methylene-19-nor-20-epi-1 α ,25-dihydroxyvitamin D₃
formula, 986
- Methylene units (MU), 874–878. *See also* Retention Indices (RI) of bile acids
- Methyl ester-acetates of bile acids, 880, 892, 896, 898, 908, 910
- Methyl ester-dimethylethylsilyl ethers (Me-DMES) of bile acids, 875, 880, 882, 884, 886, 889, 892, 894, 913
- Methyl ester-methylloxime-trimethylsilyl ether of bile acids (Me-MO-TMS), 877, 902
- Methyl ester-trimethylsilyl ethers (Me-TMS) of bile acids, 875, 878–880, 882–884, 886, 888–891, 893–897, 899, 900, 903–906, 908, 912, 913
- Methyl ethers of bile acids, 872, 891, 912
- Methyl 12-hydroxy-3-oxo-cholanoates, 877, 886
- Methyl norcholanoates, 881
- Methylloxime(s) (MO) of bile acids, 874, 877, 878, 886, 887, 892, 902
- Methyl oxo-cholanoates, 877, 886
- Methylprednisolone, 1104, 1110, 1131
acetate, 1104, 1110
hydrogen succinate, 1104
sodium succinate, 1104
suleptanate, 1134, 1149
- 6 α -Methyl-prednisolone
LC- or GC-MS, 414–423
structure, 406
- Methyltestosterone, 744, 1104, 1110, 1121, 1153
metabolism, 764
metabolism in the horse, 761
- Metyrapone (metopirone), 188
- Mibolerone, 1104, 1110
- Micellar electrokinetic capillary electrophoresis of bile acids, 867
- Micellar electrokinetic chromatography (MEKC)
of bile acids 869, 934–936
in compendial analysis, 183, 1099, 1129–1132, 1139–1143, 1145–1149, 1151, 1152
- Microemulsion electrokinetic chromatography (MEEKC)

- in compendial analysis 1131, 1132, 1143, 1145, 1148, 1150, 1152
- Micro-LC of bile acids, 867
- Microplate magnetic chemiluminescence, 702
- Mifepristone, 592
- Mineralocorticoids
 - analysis of, 384–394
 - biological activity, 333–334
 - definition, 330
- m*-Methoxyphenacyl bromide in formation of bile acid derivatives for LC, 869
- Molecular action, 164
- Molecular ion(s) during MS of bile acids, 879–881, 883, 884, 886, 887, 890, 893–896, 900, 907
- Molecularly imprinted polymers (MIP), 183–184
- Molecular weight(s) of bile acids, 881, 882
- Mometasone furoate, 1104, 1110, 1118, 1127, 1134, 1152
- Monoclonal antibodies for IA of bile acids, 939
- Monohydroxy-cholanoates, 876, 882, 884, 886, 891, 892, 908
- Monohydroxy C₂₇ sterols, 908. *See also* Sterols
- Monohydroxy-oxo bile acids, 891, 893
- MS. *See* Mass spectrometry
- MS/MS of bile acids, 901, 927–932
- Multiple bond, 5
- Multiple ion/reaction monitoring of bile acids, 907, 928
- Multiple reaction monitoring (MRM) in LC-MS, 234–236

- N**
- N*-acetylglucosaminides, 845, 857, 861, 918
- NAD⁺/NADH in bile acid enzyme assay, 871, 935, 936, 938
- NAD(P)H/FMN oxidoreductase in bile acid enzyme assay, 937
- Nandrolone, 745, 749–751, 1119, 1136, 1140
 - artefact in extraction of horse urine, 809
 - decanoate, 1104, 1110
 - endogenous production, 752
 - in equine doping, 807–810
 - in human doping, 810–813
 - in men by GC-HRMS, 810
 - metabolism, 758–760
 - phenylpropionate, 1104, 1111
 - in pregnancy, 810
 - urine specific gravity adjustment, 811
- Nano-ES of bile acids, 914
- Nano-LC of bile acids, 933–935
- Natural abundance (¹³C/¹²C ratios) in determining pool size of bile acids, 910–912
- Negative ion chemical ionization (NICI) in MS of bile acids, 911
- Neonatal bile acids, 847, 872, 877, 884, 886, 888, 889, 894, 897, 910, 911, 931, 938
- NEQAS (EQA for steroids), 1155, 1162, 1166, 1168–1170, 1172, 1173, 1180, 1181, 1183
 - estrogens, 703–704
- Nestorone, 1122, 1134, 1139
- Neuroactive C₁₉ steroids
 - actions in brain, 492–493
 - biosynthesis, 583
 - classification, 583
 - effects on neurotransmitter receptors, 584
 - GC-MS methodology, 588–589
 - measurement by GC-MS-SIM, 492–493
 - metabolism in brain and CNS, 585
 - psychopharmacological and neuro-psychiatric effects, 584–585
 - steroid profiling, 585–587
- Neurological disease in defects of 2-methyl racemase enzyme, 895
- Neurosteroids in rat brain, 851
- Neutral-loss scan in bile acid MS, 921, 928, 930
- Newman projection, 8
- n*-Hydrocarbons—use in determining methylene unit values, 875, 912
- N*-hydroxysuccinimidyl esters in NICI MS of bile acids, 910
- NIR (near infrared) spectroscopy, 1114, 1116, 1137, 1142, 1143
- Nitrotetrazolium blue in bile acid enzyme assay, 935, 936
- NMR data
 - of bile acids, 893, 895, 896
 - calcipotriol, 1042
 - 1 α ,25-dihydroxyvitamin D₃, 1042, 1045
 - double side chain vitamin D compounds, 1049
 - 3-*epi*-1 α , 25-dihydroxyvitamin D₃, 1051
 - 1 α -hydroxy-20S-formyl-pregnacalciferol-bis-O-TMSi ether, 1042
 - 1 α -hydroxyvitamin D₂, 1042
 - 1 α -hydroxyvitamin D₃, 1042
 - KH1060, 1050
 - pre-vitamin D₃, 1042
 - vitamin D₂, 1042
 - vitamin D₃, 1042

- N,O*-bis(diethylhydrogensilyl)-trifluoroacetamide in formation of bile acid derivatives, 876, 877, 911
- Nonamidated bile acids, 862, 865, 871
- Non-isotopic labels in immunoassay, 294–300
- Non-planar conformation, 8
- Non-proprietary names (INN), 14
- Nonsulphated bile acids, 938
- 4-Nor-5 α -androstane, 20
- 19-Nor-10 α -androst-4-ene-3,17-dione, 46
- Nor bile acids, 841, 879, 889, 895, 898
- Norbolethone, 747, 752
- 19-Nor-calcitriol
formula, 986
- 24-Norchenodeoxycholic acid, 889
- Norethandrolone, 745
metabolism in the horse, 762
- Norethisterone (NE), (norethindrone), 19, 593
acetate, 1104, 1124
compendial analysis, 1104, 1116, 1119, 1128, 1129, 1132–1134, 1140
- Norethynodrel, 1104
- Norgestimate, 1105, 1117, 1132, 1152
- Norgestrel, 593,
compendial analysis, 1105, 1110, 1111, 1114, 1119, 1128, 1129, 1133–1136, 1139, 1141, 1143, 1146, 1151
- Normethandrolone
metabolism in the horse, 761
- 19-Nor-testosterone, 20
- 24-Norursodeoxycholic acid, 889
- Nuclear magnetic resonance (NMR)
spectroscopy
basic principles, 63–65
Boltzman distribution, 63
macroscopic magnetization, 63
magnetic moment, 63
saturation, 63
spin I, 63
carbon-13 NMR spectra, 80–82
in compendial analysis, 1115–1117, 1133, 1136, 1138, 1139, 1144–1146, 1148, 1150, 1151
deuterium (2H), 82
experimental
acquisition time, 66
Fourier transformation (FT), 66
free induction decay (FID), 66
methods, 86–87
NMR signal, 66–67
oscillating magnetic field B_1 , 66
pulse length, 66
signal-to-noise ratio (S/N), 6
factors influencing NMR spectra
concentration effect, 73–74
dynamic processes, 72
magnetic field effect, 73–74
molecule symmetry and nuclei equivalence, 70
nuclear Overhauser effect, 73
solvent effects, 73–75
spectrum order and spin systems, 71–72
spin decoupling, 73
temperature effect, 73–74
fluorine (¹⁹F), 83–84
(HP)LC-NMR, 1099, 1124, 1133, 1134, 1139, 1144, 1148, 1151
oxygen (¹⁷O), 83
parameters
chemical shift, 67–68
lowfield (paramagnetic) shift, 67–68
upfield (diamagnetic) shift, 67–68
relaxation and relaxation times, 69–70
signal intensity, 69
signal multiplicity, 68
spin-spin coupling, 68
proton NMR spectra
coupling constants, J (H,H), 78–80
hydroxyl protons-deuterium exchange, 77
proton chemical shifts, 76
pulse sequences, 1D and 2D, 115–117
relaxation
relaxation time T_1 , 69
relaxation time T_2 , 70
spin-lattice (longitudinal), 69
spin-spin (transversal), 70
spectrometer, 65–67
superconducting magnets, 65
console, 65
structure analysis
connectivity diagrams, 85, 87–88
coupling constants, 99, 102–104
derivatisation, 107–108
molecular modeling, 108–110
nuclear Overhauser effect, 73, 105–106
relaxation times, 104–105
side-chains, 108
signal dispersion, 85
strategy and methods, 88–89
trace impurities identification, 110–114
temperature effect, 73–74
tritium (³H), 82
of vitamins D and metabolites, 1039–1054

O

- 3-O-acetylcholic acid, 17
O-(2 anthrylmethyl)hydroxylamine in LC of bile acids, 872
OCT. *See* 22-Oxa-calcitriol
Octant rule, 44, 46
ODS-silica in extraction of bile acids, 849–851
Oestrogens. *See* Estrogens
Ointment, 1109–1112, 1119, 1122, 1129, 1131, 1146, 1150, 1151, 1153
[¹⁸O] labeling of bile acids, 908, 913
Optical rotatory dispersion (ORD), 42–45
Osteopontin, 978, 980
OVEIA^R dual analyte EIA, 569
Overpressured layer chromatography (OPLC). *See* Thin-layer chromatography (TLC)
22-Oxa-calcitriol (OCT)
 formula, 986
 LC-MS assay, 1032
 LC-separation of metabolites, 1002
 MS characterization of metabolites, 1064
Oxandrolone, 745, 1105, 1107, 1110
Oxidation of bile acids, 886, 902
Oxidation-reduction of estrogens, 609, 611, 621, 672, 673
6 β ,19-Oxidoandrosta-1,4-dien-17-one, 47
6 α ,7 α -Oxidopregn-4-ene-3,20-dione, 47
Oxidoreductase deficiency (ORD), 245, 246
Oxidoreduction of bile acids, 841, 842, 874, 884, 886, 902
Oximes of bile acids, 858, 872, 874, 877, 886, 887, 892, 902
3-Oxoandrost-4-en-17 β -yl acetate, 17
3-Oxo- Δ^1 -bile acid, 872, 888
Oxo bile acids, 841, 846, 848, 859, 872, 874, 877, 886–888, 890, 892, 893, 909
6-Oxo bile acids, 890
7-Oxo bile acids, 887, 891, 892
12-Oxo bile acids, 893
24-Oxo bile acids, 900
Oxo/carbonyl groups in bile acids, 864, 871–874, 877, 878, 886, 891, 902
3-Oxo-cholest-4-en-26-oic acid, 846
18-Oxo-cortisol
 synthesis, 333
7-Oxo-DHEA, 56
Oxo-hydroxy bile acids, 874, 886, 893
3-Oxo structure (group) of bile acids, 872, 877, 886–888, 935, 936, 938
3-Oxo- Δ^4 -structure of bile acids, 845, 858, 872, 887
Oxygen (¹⁷O) NMR, 83
18-Oxygenated corticosteroids, 390–394
 in differential diagnosis of primary hyperaldosteronism, 384, 391
 18-oxylucocorticoids, 392, 394
 18-oxyminalocorticoids, 390–393
Oxymesterone, 745
 detection in urine by SIM, 786
Oxymetholone, 745, 1105, 1110
 detection in urine by SIM, 786
 metabolism in the horse, 761
Oxysterol 7 α -hydroxylase, 882, 915
Oxysterols, 244, 876, 882, 896, 908, 932
- P**
Pancuronium bromide,
 compendial analysis, 1100, 1105, 1122, 1133, 1140, 1151, 1153
Paper chromatography, 194, 197
Paramethasone acetate, 1105, 1111
Parathyroid hormone (PTH), 975
Paricalcitol, 1105, 1110
Penalty Box plots, 1173
Pentafluorobenzyl ester DMES ethers of bile acids, 910, 911
Pentafluorobenzyl ester of bile acids, 878
Pentafluorobenzyl ester-TMS ethers of bile acids, 912
Pentafluorobutyrate of bile acids, 908
Perfluoroacyl derivative of bile acids, 873
Permethylation derivatives of bile acids, 912
Peroxidase in bile acid enzyme assay, 938, 939
Peroxisomal disorders (peroxisomopathies), 881, 895, 897, 899, 900, 911, 930, 931
Pharmacopoeias (general), 1098, 1100–1109, 1111, 1114, 1118, 1122, 1133, 1137, 1138
 European Pharmacopoeia (Ph. Eur.), 1100–1109, 1114, 1137, 1150
 Pharmacopoeias (general) (*cont.*)
 Japanese Pharmacopoeia (Ph. Jp.), 1100–1109, 1114, 1150
 United States Pharmacopoeia (USP), 1100–1109, 1114, 1127, 1135, 1137, 1152
Phenacyl ester in bile acid LC, 869
Phenazine methosulphate (PMS), 938
Phenyl methyl polysiloxane in bile acid GC, 874
'Phosphatonin' hormone, 975
PHP-LH-20 for separation of bile acid conjugates, 853, 936
Picolinoyl ester in bile acid LC-MS, 931

- Pipecurionium bromide, 1135, 1136
- pK_s of bile acid conjugates, 854, 863, 867, 918
- Plant sterols, 873, 882
- Plasma free progesterone
- equilibrium dialysis, 576
 - plasma free progesterone estimates, 577
 - role of free/ protein bound progesterone, 575
 - steady state gel filtration, 576
- Plasma resonance biosensors, 320–321
- Plasticizers as non-specific artefacts in GC of bile acids, 878
- p*-Nitrobenzyl ester
- for LC of bile acids, 869
- p*-Nitrophenyl ester in MS of bile acids, 910
- Polydeoxycholic acid, 842
- Positional isomers of bile acids, 865, 878, 886, 890, 902, 908
- Potential bridging molecule synthesis, 512–513
- Prasterone sodium sulfate, 1105, 1107
- Precolumn derivatization for bile acid LC, 869, 870, 872, 938
- Precolumn fluorescent labeling for bile acid LC, 870
- Precursor-ion scan in bile acid MS, 928
- Prednicarbate, 1105
- Prednisolone
- acetate, 1105, 1110, 1119, 1129, 1147, 1148
 - compendial analysis, 1105, 1110, 1111, 1116, 1121, 1124, 1127, 1129, 1131, 1133, 1134, 1140, 1145, 1147, 1148
 - hemisuccinate, 1105, 1142
 - LC-or GC-MS, 414–423
 - pivalate, 1105
 - sodium metasulfobenzoate, 1116
 - sodium phosphate, 1105, 1110, 1122
 - sodium succinate, 1105, 1115
 - structure, 406
 - tebutate, 1105, 1110
- Prednisone
- compendial analysis, 1105, 1110, 1131, 1149
 - LC-or GC-MS, 414–423
 - structure, 406
- Pregnancy
- bile acids in, 855, 856, 874, 889, 937, 938
 - increase in nandrolone production, 810
- Pregnane, 1, 13
- 5 β -Pregnane, 13
- 5 β -Pregnane-3 α ,20 α -diol, 4
- (20S)-5 β -Pregnane-3 α ,20-diol, 7
- (20R)-5 β -Pregnane-3 α ,20,21-triol, 7
- Pregnanediol, 7, 581–582
- 5 α Pregnanediones, 580–581
- 5 β Pregnanediones, 580–581
- 17 ξ -Pregnan-20-ones, 45
- Pregn-4-ene-3,20-dione, 12
- Pregnenolone, 579–580
- structure, 331
- Premarin, 619, 661, 681
- Pre-vitamin D₃
- ¹³C-NMR data, 1042–1043
 - equilibrium with vitamin D₃-investigation of reaction mechanism by NMR, 1053
 - formula, 968
- Primary aldosteronism, 384, 391
- aldosterone:renin ratio, 385
- Primary bile acids, 842, 847, 884, 886, 895, 896, 908, 909, 914, 937
- Primary standards, 1161
- Proficiency testing, 1167
- Profiles, 203, 238
- GC-MS data, 250–251
- ProgBA, 1184
- Progestagens
- GC-MS, 573–574
 - immunoassays, 568–573
 - LC-MS, 574–575
- Progesterone, 2, 12
- automated immunoassays, 573
 - bioassays, 563
 - Biocor biosensor, 572
 - biosynthesis, 560
 - brain and peripheral nervous system biosynthesis, 583
 - identification, 585–589
 - neurotransmitter receptors, 584–585
 - Carbon-13 shifts in NMR, 98
 - chemiluminescence immunoassay, 571
 - compendial analysis, 1105, 1110, 1111, 1119, 1124, 1130, 1132, 1145
 - competitive protein binding assays, 564–565
 - discovery and isolation, 559
 - double isotope derivatisation assay, 564
 - Elecsys assay, 571
 - enzyme immunoassay (EIA), 568
 - fluorimetry, 564
 - gas-liquid chromatography/mass spectrometry, 573–574
 - Immulite assay, 571
 - Kryptor assay, 571

- liquid chromatography-tandem mass spectrometry (LC-MS/MS), 574–575
 - metabolism, 562–563
 - non-radioactive labels, immunoassay
 - chemiluminescence, 571–572
 - enzyme labels, 568–570
 - surface plasmon resonance labels (SPR), 572–573
 - time-resolved fluorescence labels/ DELFIA assays, 570–571
 - normal values in plasma, 561
 - ovulation timing measurements, 561
 - proton chemical shifts of steroids, 96–97
 - radioimmunoassay
 - antisera, 566
 - chromatographic separation, 565
 - direct (non-extraction) immunoassays, 566–567
 - haptens, 565
 - [125 I] radioligands, 567–568
 - solvent extraction, 566
 - secretion, 561
 - spectrophotometry, 563–564
 - structure, 331
 - surface plasmon resonance (SPR) assay, 572
 - Progesterone-11 α -hemisuccinate as immunogen, 287
 - Progesterone measurement by immunoassay
 - bridge recognition, 291
 - chemiluminescent assay, 297
 - direct measurement, 302
 - plasma resonance biosensors, 321
 - in saliva, 303
 - Prostanozolol, 746
 - Prostate, 458, 467, 491, 521, 537
 - androgens in measured by RIA, 537
 - cancer of,
 - aggressiveness, index of, 674
 - androgens in, 521
 - 1,25(OH)₂D₃ in, 976
 - elocalcitol, use in, 986
 - 25-OHD₃ concentrations in, 984
 - role of estradiol in, 617–619
 - modulation of 5 α -reductase in, 458
 - 5 α -reductase in, 491
 - UTPs and prostate tumor cells, LNCaP, 467
 - Protein binding of bile acids, 848–850, 852
 - Proton NMR spectra
 - coupling constants, J (H,H)
 - allylic couplings, 80
 - geminal coupling ²J (H,H), 78–79
 - homoallylic couplings, 80
 - vicinal coupling ³J (H,H), 79
 - W coupling, 80
 - hydroxyl protons–deuterium exchange, 77
 - proton chemical shifts, 76
 - proton chemical shifts of steroids, 96–97
 - Provitamins. *See also* Ergosterol; 7-Dehydrocholesterol
 - PT (proficiency testing), 1167
 - Purification of C₁₉ steroids, 463–465, 472–478
 - Pythocholic acid, 893, 894
- Q**
- QA of estrogen assays, 702–704
 - external quality standards, 703
 - Levy-Jennings plots, 703
 - NY state standards, 704
 - quality of standards, 702
 - validation, 702
 - variance in assay methods, 703
 - vitamins D metabolite assays, 1019, 1040, 1056, 1059
 - Q-TOF–mass spectrometry, 129
 - Quadrupole analysers/instruments for bile acid MS, 883, 907
 - Qualitative analysis, GC-MS of bile acids, 869, 879
 - Quality, 1155
 - Quality assurance, 165, 1155–1188
 - androgen assays, 531
 - corticosteroid assays, 340, 356, 359
 - DEQAS, 1056, 1059, 1183
 - EQAS, 1155, 1167
 - EQA Advisory Panels, 1168
 - EQA organiser, 1167
 - EQA Steering Committee, 1168
 - European based QA/PT schemes, 1184
 - NEQAS, 1155, 1162, 1166, 1168–1170, 1172, 1173, 1180, 1181, 1183
 - Quality specifications, 1161, 1165
 - Quantification of bile acids, 879, 907–913, 923, 930–932, 935–939
 - Quasi-axial, 9
 - Quasi-equatorial, 9
 - Quinuclidine in bile acid LC, 870
- R**
- Rac-estradiol, 2
 - Racemization of bile acids, 895
 - Radioimmunoassay (RIA) of androgens, 502, 516–521, 535–537

- Radioimmunoassay (RIA) of bile acids, 938–939
- Raman spectroscopy, 1114, 1115, 1140, 1142, 1148, 1149
 backbone vibrations, 148
 estrone, 150
 resonance Raman spectroscopy (RRS), 151
 sample arrangement, 149
 stretching bond frequencies, 148–149
 surface-enhanced Raman spectroscopy (SERS), 151
 surface-enhanced resonance Raman spectroscopy (SERRS), 151
- Random access material (RAM), 183–184
- Randox International Quality Assessment Scheme (RIQAS), 1185
- Rapid filtration transport assays
 of androgens, 468
- Rat liver tissue–bile acids in, 866, 909, 910
- RCPA, 1185
- Recovery, 1161, 1178
- Recycling sorbent extraction of bile acids, 851
- Red shift. *See* Bathochromic effect
- Reference measurement system, 1159
- Reference standards (authentic compounds)
 for bile acid analysis, 870, 879, 880, 883, 885, 894, 895, 901
- Reichstein's compound F, 13
- Reichstein's compound M, 13
- Reichstein's compound Q, 13
- Repetitive scan recording (repetitive scanning)
 in bile acid MS, 884, 889, 907, 912, 913
- Reproducibility, 1164
- Resazurin/resorufin in bile acid enzyme assay, 935, 936
- Resonance Raman spectroscopy (RRS), 151
- Response factors of bile acids during GC, 878, 908, 912
- Restricted access material (RAM), 183–184
- Retention indices (RI) of bile acids, 874–876, 878–880, 883, 885, 890, 893, 898, 907
- Retro-Diels-Alder elimination in GC-MS of bile acids, 887
- Reversed-phase partition chromatography of bile acids, 862, 864–866, 868, 922
- Rhodamine isothiocyanate, 299
- Rickets
 global health issue, 1067
 treatment with D₂, 984
 type 1 (D-dependency), 975
 Vit D deficiency, 974, 983
- Rimexolone, 1105, 1110
- RIQAS. *See* Randox International Quality Assessment Scheme
- Ro-26-9228. *See* Elocalcitol
- Rocuronium bromide, 1105
- R or S configurations, 6
- Royal College of Pathologists
 of Australasia, 1185
- R/S system, 5
- S**
- Salivary progesterone
 collection precautions, 578
 detection of ovulation, 579
 normal concentrations, 578
 progesterone creams, 579
 salivary flow rate influence, 577
- Salivary steroids, 184
- Sample matrices, 166
- Sample preparation for immunoassay
 direct assays, 302–303
 extraction and chromatography, 301
- Sample preparation/work-up of bile acids, 847–861, 872, 888, 891, 895, 898, 908, 930
- Sample type for immunoassay
 saliva, 303–305, 317
 serum, 292, 302, 303, 314, 319
 urine, 305–306
- Scatchard analysis, 290
- Scillarenin, 22
- Scillaridin and scillarhenin, 39
- Secondary bile acids, 842, 891, 893, 908, 909
- SEKK, 1184
- Selected ion monitoring (SIM)/recording (SIR) of bile acids, 907, 909, 910, 912, 913
- Sephadex LH-20 derivatives in bile acid separation, 853, 858
- Sephadex LH-20 in bile acid separation, 857
- Sephadex LH-20 separation of estrogens, 631, 633–635, 672, 676–677, 690
- Sequence rule, 5
- Sex-hormone binding globulin (SHBG), 609, 627, 655
- Short-chain bile acids, 846, 881
- Side-chain cleavage of bile acids, 881, 897, 902, 916
- Side-chain hydroxylation of bile acids, 881, 882, 896, 897
- Side chain in bile acids, 841, 844, 854, 859, 866, 869, 870, 880, 881

- Side-chain oxidation of bile acids, 887, 892, 895, 899, 900
- α -Side of bile acids, 865, 866
- β -Side of bile acids, 863, 865, 866
- Signal/noise ratio in bile acid assay, 870, 879, 910
- Silicic acid in bile acid separation, 857
- Silylation
- of bile acids, 873, 874, 877, 889
 - formation of enol derivatives, 783–785
 - mechanism, 784
- Silyl ethers of bile acids, 880
- Sitosterol, 11
- β -Sitosterol, 12
- Size exclusion chromatography, 188
- Skin
- synthesis of vitamin D₃, 968–970
- SKML, 1184
- Smith Lemli Opitz syndrome (SLO), 400, 892
- Sodium borodeuteride reduction
- of bile acids, 910
- Sodium 17-oxoandrost-5-en-3 β -yl sulphate, 17
- Soft ionization of bile acids, 842, 879, 901, 902
- 5 ξ -Solanidan, 23
- Solanidin, 23
- 5 ξ -Solasodan, 23
- Solasodin, 23
- Solid-phase extraction (SPE), 174–180, 469–471, 486–491, 506, 509
- bile acids/sterols, 849–851
 - of estrogens, 701
- Solubility limitations in bile acid LC, 851, 864–866
- Solvent extraction, 169–174
- of bile acids, 848–849
 - of androgens, 469–470
 - of corticosteroids, 342–346
 - of estrogens, 621–627
 - of progestagens, 566
 - of vitamins D metabolites, 990–992
- Solvolytic of bile acid conjugates, 860, 891, 898, 902, 909, 937, 938
- Specific ion monitoring, 492–500
- Spectropolarimetry. *See* Circular dichroism spectroscopy
- Spiking, 1166
- Spirolactone, 1106, 1110–1113, 1115, 1123, 1133, 1140, 1142, 1146, 1148, 1149
- Spirostane, 22
- (25R)-Spirost-5-en-3 β -ol, 12
- SP-LH-20 cation exchanger for bile acid separation, 858
- Stable-isotope dilution analysis of bile acids, 879, 907–910, 912, 913, 931
- Stable-isotope MS, 484–491
- Staggered conformation, 8
- Stanozolol, 745, 757, 1100, 1106, 1111, 1116
- metabolism, 763
- Stationary phase in bile acid separation, 850, 864, 865, 874–877
- Stenbolone, 745
- Stereochemistry of bile acids, 844, 878, 879, 883, 889–891, 895, 896, 898, 900, 921
- Steric environment/hindrance in bile acids, 870, 873, 874
- Steroid conjugates
- hydrolysis of, 180–182
- Steroid glucuronides, 243, 244
- LC-MS of, 181
- Steroid hormone assays by LC-MS
- adrostenedione, 239
 - aldosterone, 238
 - 11-deoxycortisol, 238
 - 21-deoxycortisol, 233
 - DHEA/DHEA sulphate, 239
 - estrone/estradiol, 238
 - 17-hydroxyprogesterone, 232
 - neurosteroids, 239
 - profiles, 203, 238
- Steroid nucleus (rings) in bile acids, 865, 866, 880, 881
- Steroid profile, 394–405
- in plasma, 403–404
 - in tissues, 404–405
 - in urine, 397–402
- Steroid sulphates, 240, 241
- LC-MS of, 242–243
- Sterol 27-hydroxylase deficiency, 882, 915
- Sterols, 851, 852, 873, 876, 881, 882, 886, 887, 892, 896, 908, 921, 931. *See also* Bile alcohols
- Stir bars, use in extraction/derivatisation, 179–180
- Straight-phase/normal-phase/adsorption chromatography of bile acids, 856–857, 861, 865, 869
- Streptavidin, 571
- Strophantidin, 22
- Structural elucidation/information of bile acids, 876, 879, 880, 882, 886, 892, 896, 897
- Sulphohydrolases in hydrolysis of bile acid sulphates, 860, 937

- Supercritical fluid chromatography (SFC) and extraction, 1121, 1122, 1136, 1138, 1139, 1142, 1143, 1146, 1148, 1153
- Supercritical fluid extraction (SFE), 472
- Suppositories, 1110, 1122, 1153
- Surface-enhanced Raman spectroscopy (SERS), 151
- Surface-enhanced resonance Raman effect (SERRS), 151
- Syn/anti* isomers of bile acid derivatives, 872, 877, 887
- Synergistic/additive effects of estrogens, 692
- Synthetic corticosteroids, 405–424
 - analysis in body fluids, 407–424
 - GC-MS, 410–412, 414–423
 - LC-MS, 412–423
 - metabolism, 407
 - structures, 406
- Synthetic progestagens
 - alphadolone acetate, 587, 590
 - alphaxolone, 587, 590
 - cyproterone acetate, 590
 - flurogestone acetate (FGA), 591
 - gestodene, 591
 - medroxyprogesterone acetate, 591–592
 - mifepristone, 592
 - norethisterone (NE), 593
 - norgestrel/levonorgestrel, 593
 - structures, 560
- T**
- Tablets
 - compendial analysis, 1099, 1110–1112, 1114, 1116, 1118, 1119, 1121, 1122, 1124, 1127, 1131, 1133, 1140, 1142, 1144, 1145, 1148–1153
- Tachysterol₃
 - formula, 968
- Tandem mass spectrometry (TMS), 311, 315, 320, 1160, 1162, 1185
- Target value, 1167, 1171
- Tauro- Δ^{22} -muricholic acids, 898
- TBDMS-imidazole in formation of bile acid
 - TBDMS ethers, 874
- TEAP-LH-20 for separation of bile acid conjugates, 853, 854
- Testane, 13
- Testolactone, 1106, 1111
- Testosterone, 10, 238, 608, 609, 616, 654, 655, 667
 - Carbon-13 shifts in NMR, 98
 - compendial analysis, 1106, 1110, 1116, 1152
 - cypionate, 1106, 1116
 - enantate, 1106
 - metabolism, 758–760, 819
 - propionate, 1106
 - proton chemical shifts of steroids, 96–97
 - in sports doping, 802–807
- Testosterone acetate, 17
- Testosterone:epi-testosterone (T:E ratio) ratio, 802–806
 - endogenous sources of epitestosterone, 804–805
 - investigations following increased ratio, 805, 817–821
 - within-subject variation, 806
- Testosterone measurement, 1160
 - cross reactions in, 292–293, 313
 - direct measurement, 302
 - by immunoassay, 288–313
 - inaccuracy of measurement, 311, 313
- Tetrabutylammonium ions in ion-pair LC
 - of bile acids, 868
- Tetrahydrogestrinone (THG), 59, 754, 768–769, 791
 - LC-MS/MS, 791
 - metabolism, 768
 - not detectable in GC-MS screen, 755, 791
 - structure, 747
 - synthesis from gestrinone, 755
- Tetrahydroxy bile acids, 857, 882, 884, 889, 890, 894, 897, 899–901
- 1 β ,3 α ,7 α ,12 α -Tetrahydroxy-5 β -cholanoic acid, 884
- 2 β ,3 α ,7 α ,12 α -Tetrahydroxy-5 β -cholanoic acid, 884
- 3 α ,7 α ,12 α ,19-Tetrahydroxy-5 β -cholanoic acid, 894
- 3 α ,7 α ,12 α ,23-Tetrahydroxy-5 β -cholanoic acid, 899. *See also* Hammarsten's α - and β -phocaecholic acids
- 3 α ,4 β ,7 α ,12 α -Tetrahydroxy-5 β -cholanoic acid, 889
- 3 α ,7 α ,12 α ,22-Tetrahydroxy-5 β -cholestanoid acid, 897
- 3 α ,7 α ,12 α ,23-Tetrahydroxy-5 β -cholestanoid acid, 899
- 3 α ,7 α ,12 α ,25-Tetrahydroxy-5 β -cholestanoid acid, 900
- 3 α ,7 α ,12 α ,26-Tetrahydroxy-5 α -cholestanoid acid, 901
- 3 α ,7 α ,12 α ,26-Tetrahydroxy-5 β -cholestanoid acid, 901

- 3 α ,7 α ,12 α ,22-Tetrahydroxy-5 β -cholestano-26,22-lactone, 897
- (22R,23R)-2 α ,3 α ,22,23-Tetrahydroxy-7-homo-5 α -ergostabicarbo-5,7-lactone, 7
- (22R,23R,24R)-2 α ,3 α ,22,23-Tetrahydroxy-7-homo-5 α -homo-24-methyl-5 α -cholestabicarbo-5,7-lactone, 7
- THCA, 895, 911
- Thermal degradation of bile acids in GC, 873, 878
- Thermochemiluminescence in immunoassay, 296
- Thermospray ionization of bile acids, 901
- Thermospray (TS) mass spectrometry, 123
- Thin-layer chromatography (TLC), 193–197
- in compendial analysis, 1099, 1101–1106, 1108–1110, 1114, 1118–1121, 1133, 1134, 1137–1140, 1142, 1143, 1145–1153
- high-performance thin-layer chromatography, 1118, 1119, 1121, 1138, 1139, 1143, 1145, 1146, 1149, 1151, 1153
- overpressured layer chromatography (OPLC), 1119–1121, 1138, 1140, 1143, 1146, 1152
- TLC densitometry, 1109, 1114, 1118, 1138, 1142, 1145, 1146, 1148, 1149, 1151, 1153
- Thyroid-stimulating hormone (TSH), 310, 318
- Time-resolved fluorescent immunoassays, 299–300, 306, 516–521
- Titration, titrimetry, 1098, 1100–1111, 1137
- Torsional strain, 8
- Total analytical error, 1165
- Total syntheses, 2
- Traceability, 1158
- chain, 1158, 1161
- Transcortin. *See* Cortisol binding globulin
- Traumatic brain injury (TBI), 586–587
- Trenbolone, 745, 757, 791
- metabolism in the horse, 758, 760
- Trenbolone acetate, 1106
- Trestolone
- in treatment of muscle wasting, 745
- Triamcinolone, 1106, 1108, 1110, 1111, 1122–1124, 1131, 1145
- acetanide, 1106, 1110, 1112, 1122–1124, 1133, 1141, 1142, 1146, 1148, 1151
- diacetate, 1106, 1110, 1122
- hexacetanide, 1106, 1110, 1123
- LC-or GC-MS, 414–423
- structure, 406
- Triazoline adducts of vitamin D metabolites formulae, 1013–1014
- Triethylamine sulphate (TEAS), 850
- Trifluoroacetate derivatives of bile acids, 872, 873, 878, 880, 882, 892, 908, 909
- Trihydroxy bile acids, 859, 876, 882, 889, 890, 893–895, 897–900, 930
- 3 α ,7 α ,16-Trihydroxy-5 β -cholanoic acid, 894
- 3 α ,6 α ,12 α -Trihydroxy-5 β -cholanoic acid, 889
- (25R)3 α ,7 α ,12 α -Trihydroxy-5 β -cholestanoic acid, 895
- 3 α ,7 α ,15 α -Trihydroxy-5 β -cholanoic acid, 893
- 3 α ,7 α ,15 β -Trihydroxy-5 β -cholanoic acid, 893
- 3 α ,4 β ,7 α -Trihydroxy-5 β -cholanoic acid, 889
- 3 α ,6 α ,7 α -Trihydroxy-5 β -cholanoic acid (Hyocholic acid), 889, 890
- 3 α ,7 α ,24-Trihydroxy-5 β -cholestanoic acid, 899
- 3 α ,7 α ,12 α -Trihydroxy-5 β -cholestanoic acid, 895, 911, 930. *See also* THCA; Coprostanic acid
- 3 α ,7 α ,12 α -Trihydroxy-27a,27b-dihomo-5 β -cholestane-26,27b-dioic acid, 896, 911. *See also* C₂₉ dicarboxylic bile acid
- 3 α ,7 α ,12 α -Trihydroxy-24-oxo-5 β -cholestanoic acid, 900
- 11 β ,17,21-Trihydroxypregn-4-ene-3,17-dione, 12
- 1 α ,24(R),25-Trihydroxyvitamin D₃
- formula and DBP-and VDR-binding affinities, 972–973
- 25,26-Trihydroxyvitamin D₃
- formation of, 973
- formula and DBP-and VDR-binding affinities, 972–3
- GC-MS of, 1029
- 7-Trimethylsiloxy group in bile acids, 887, 891
- 1,3-Trimethylsiloxy structure of bile acids, 884, 888
- 3-Trimethylsiloxy- Δ^4 structure of bile acids, 889
- Trimethylsilyl (TMS) ether derivatives of bile acids, 872–875, 877–884, 886, 887, 889–897, 901, 902, 908, 912, 913
- Tritium (³H) NMR, 82
- Trivial names, 13
- Trueness, 1158, 1165, 1167. *See also* Bias
- U**
- UDP glucuronyl transferases (UGTs)
- properties of anabolic steroid conjugation, 771–775
- Triazoline adducts of vitamin D metabolites

- UK National Quality Assurance Advisory Panel for Chemical Pathology, 1172
- UK NEQAS for Steroid Hormones, 1155, 1162, 1168
- Ultra-performance liquid chromatography (UPLC) of bile acids, 934–935. *See also* Liquid chromatography (LC)
- Ultraviolet (UV) absorbance
in LC, 222–224
on TLC plates, 193
- Ultraviolet absorption spectroscopy
absorbance, 31
antibonding π -orbitals, 29
 n / π^* transitions, 30
 π / π^* transitions, 30
 σ / σ^* transitions, 40
chiroptical properties, 42–47
5 α -androstan-16-one, 43
A-nor-5 α -androstan-2-one, 43
circular dichroism, 43–47
Cotton effect, 42–46
octant rule, 44, 46
optical rotatory dispersion, 42–45
17 ξ -pregnan-20-one, 45
specific optical rotation, 42
symmetry rules, 46
cholesta-4,6-dien-3 β -ol, 30
cholesta-5,7-dien-3 β -ol, 29
chromophores, 29, 34–40
aromatic chromophores, 40
buta-1,3-diene, 34
cross-conjugated diene, 38
5,7-diene, steroidal, 35
enones, calculations, 38
steroidal 5,7,10(19)-triene (vitamin D series), 36
3,5,7-triene, steroidal, 35
Woodward-Fieser-Scott rules, 36–37
in compendial analysis,
detector, 1098, 1101–1109, 1114, 1122–1124, 1127, 1128, 1134, 1135, 1140, 1141, 1143, 1144, 1146, 1152
spectrophotometry, 1098, 1100–1106, 1108, 1111–1114, 1123, 1127, 1133, 1136, 1137, 1142, 1144, 1146, 1150, 1153
- dansyl derivatives, 41
 $\Delta^9(11)$ -dehydroergosterol, 41
digitoxigenin, 39
equilenin and equilin, 40
1,3,5(10)-estratriene-3,17 β -diol, 33
fluorescence, 40–42
17 β -hydroxyandrosta-4,6-dien-3-one, 33
17 β -hydroxyandrost-4-en-3-one, 33
instrumentation, 31
Lambert's and Beer's law, 30
molar absorptivity, 31
molar extinction coefficient, 31
pH effect, 33
red shift, bathochromic effect, 32
solvents, 32–33
spectrum measurement, 31–32
wavelength (λ), nanometers, 29
- Ultraviolet (UV)
detector, 1098, 1101–1109, 1114, 1122–1124, 1127, 1128, 1134, 1135, 1140, 1141, 1143, 1144, 1146, 1152
spectrophotometry, 1098, 1100–1106, 1108, 1111–1114, 1123, 1127, 1133, 1136, 1137, 1142, 1144, 1146, 1150, 1153
- Unbiased analysis of bile acids, 879, 907
- Unbound steroid, 184
- Uncertainty, 1158
- United States Pharmacopeia (USP). *See* Pharmacopoeia
- Unruptured luteinized follicle syndrome, 561
- Unsaturated bile acids/bile alcohols, 841, 846, 881, 882, 886, 888, 891, 892, 894, 898, 900, 921
- Uridine phosphoGTs (UGTs), 466
- Urinary metabolite, 18
- Urine
specific gravity, WADA adjustment for, 811
- Ursodeoxycholic acid (UDCA, ursodiol), 13, 863, 864, 867, 870, 871, 874, 875, 879, 889, 891, 897, 898, 909, 911, 937, 939, 1106, 1121, 1128, 1141, 1150)
- UV-detection in LC of bile acids, 862, 866, 868, 869, 871, 937, 938
- V**
- Validation of immunoassays
calibration curves, 310
imprecision, 308–309
inaccuracy, 311
interference, 311–314
recovery and bias, 310
sensitivity, 310
- Varanic acid, 899
- VDR. *See* Vitamin D receptor

- VDR-binding affinities
of vitamin D₃ metabolites, 972
- Vecuronium bromide, 1106
- Vicinal glycols in bile acids, 870, 873, 876,
877, 882, 890, 896, 911
- Vitamin, 11
- Vitamin D₂. *See also* Ergocalciferol
absorption as chylomicrons, 972
¹³C-NMR data, 1042
extinction coefficient, 970
formula, 968, 984
metabolite identification by NMR, 1052
UV absorption maxima, 970
- Vitamin D₃
biochemistry, 970–984
 anabolism/catabolism, 973
 cytochromes P450, 973
 skin synthesis, 968–969
chemistry, 969–970
¹³C-NMR data, 1042
formula, 968
hydroxylation of, 976–682
metabolite of, 972
UV spectrum, 971
- Vitamin D binding globulin, 971. *See also*
D binding protein (DBP)
concentration in blood, 972
- Vitamin D binding protein (DBP)
binding affinities of D₃ metabolites, 972
- Vitamin D EQA Scheme (DEQAS), 1183
- Vitamin D hydroxylases. *See* Cytochromes
p450
- Vitamin D receptor (VDR)
binding affinities of D₃ metabolites, 972
co-factors in transcription, 978
- Vitamin D responsive element (VDRE),
974–981, 1061
- Vitamin D status
use of 25-OHD assays, 1054–1059
- Vitamins D (vitamins D₂ and D₃)
analysis of D and metabolites, 987–1039
accuracy considerations, 989
in clinical biochemistry, 1054–1059
commercial assays for 25-OHD,
1056–1059
extraction
 Bond-Elut, 994–995
 immunoaffinity, 997–998
 liquid-liquid, 989–992
 Oasis-HLB, 997
 Sep-Pak, 994–995
 solid-phase (SPE), 992–997
in foodstuffs, 1065–1068
immunoassay and saturation analysis,
1015–1018
internal standards, 998–1000
introduction, 987–989
mass spectrometry
 GC-MS, 1022–1029, 1031
 LC-MS, 1031–1032, 1039
analysis of vitamin D analogues,
1059–1061
basic formulae, 968
biochemistry, 970–984
chemistry, 969–970
International Unit of, 1054
IUPAC-IUB nomenclature, 969
liquid chromatography, 1000–1015
 columns, 1000–1003
 detection, 1006–1015
 electrochemical, 1007, 1010
 fluorescence, 1011–1015
 photodiode array, 1008–1010
 radioactivity, 1002, 1011, 1012
 eluting solvents, 1003–1006
metabolic studies, 1061–1067
molecular weights
nomenclature, 967
NMR spectroscopy, 1039–1054
pro-drugs and analogues, 985–987
 source of, 969
separation
 by LC, 1000–101506
 LC-fluorescence, 1011–1015
 LC-radioactivity, 1011–1012
 paper chromatography, 996
 by TLC, 996
storage in adipose tissue, 972
triazoline adducts, 1013–1014
use of LC-UV, 1006–1010
- Volatile buffer in bile acid LC, 866, 869
- W**
- Wales External Quality Assessment Scheme
(WEQAS), 1181
- WEQAS. *See* Wales External Quality
Assessment Scheme
- Wintersteiner's compound F, 13
- Woodward-Fieser-Scott rules, 36–37
- World Anti-Doping Agency (WADA),
748, 749, 754, 775, 776, 781,
785, 787–788, 791, 795–798,
802–803, 806, 810–812, 814,
818, 820
agreement of relative retention times, 796

World Anti-Doping Agency (WADA) (*cont.*)
collection and handling of urine samples,
775–778
confirmatory analysis, 795–801
criteria for diagnostic ions in MS,
796–801
for identification of compounds, 795
sample preparation, 781–783
trimethylsilylation, 781–785
urine specific gravity, adjustment
for, 811

for use of $^{13}\text{C}:^{12}\text{C}$ ratios, 818–821
use of GC-MS, 785–788

X

Xenobiotic steroids. *See* Synthetic steroids
X-ray diffraction, 151–152

Z

Zellweger syndrome, 896, 897